<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        33-355-06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2006
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Ebetaxel 300mg/50ml
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PACLITAXEL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        6
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1762.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value=" Fareva Unterach GmbH " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                             Fareva Unterach GmbH 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            EBEWE PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01CD01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Paclitaxel 6 mg/ml is a antineoplastic or anticancer agent. It may stop cancer cells from dividing and growing.</p><p>&nbsp;</p><p>Paclitaxel 6 mg/ml is used to treat different types of cancer, i.e.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast cancer</p><p>o&nbsp;&nbsp; treatment of early breast cancer after surgical removal of the primary tumor following treatment with anthracycline and cyclophosphamide (AC) as an additional treatment</p><p>o&nbsp;&nbsp; as first therapy for advanced or spreading breast cancer. Paclitaxel 6 mg/ml is either combined with an <em>anthracycline </em>(e.g. doxorubicin) or with a medicine called <em>trastuzumab </em>(for patients for whom anthracycline is not suitable and whose cancer cells have a protein on their surface called HER 2, see package leaflet of trastuzumab).</p><p>o&nbsp;&nbsp; as a second-line treatment for patients who have not responded to standard treatments using anthracyclines, or for whom such treatment should not be used.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ovarian cancer</p><p>o&nbsp;&nbsp; as first therapy of advanced ovarian cancer, or in patients with residual tumor &gt;1 cm after initial surgury in combination with cisplatin</p><p>o&nbsp;&nbsp; after standard platinum-containing medicines have been tried but did not work.and</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Advanced non-small cell lung cancer:</p><p>o&nbsp;&nbsp; in combination with cisplatin, when surgery and/or radiation therapy aren&rsquo;t suitable.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; AIDS-related Kaposi&rsquo;s sarcoma:</p><p>o&nbsp;&nbsp; where another treatment (i.e. liposomal anthracyclines) has been tried but did not work.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Paclitaxel 6 mg/ml</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>allergic </strong>to paclitaxel or any of the other ingredients of this medicine (listed in section 6), in particular macrogolgycerol ricinoleate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are breast-feeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your white blood cell count (neutrophil count) is below 1.500 cells per &micro;l (for cancer patients) or below 1.000 cells per &micro;l (for Kaposi&rsquo;s sarcoma patients). This is determined by the medical staff.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have Kaposi&rsquo;s sarcoma and a serious and uncontrolled infection infection at the same time</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from severe liver disorder</p><p>If any of these apply to you, <strong>talk to your doctor before starting treatment with Paclitaxel 6 mg/ml.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p>Talk to your doctor or pharmacist or nurse before using Ebetaxel. Take special care</p><p><strong>&nbsp;</strong></p><p><strong>To minimize allergic reactions, </strong>you will be given other medicines before you receive Paclitaxel 6 mg/ml.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you notice marked allergic reactions (e.g. difficulty breathing, shortness of breath, chest tightness, drop in blood pressure, dizziness, lightheadedness, skin reactions such as swelling or rash)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have <strong>fever, severe chills, sore throat or mouth ulcers </strong>(signs of bone marrow suppression).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a heart conduction problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have serious liver problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have previously had problems in the arms or legs, such as numbness, weakness, tingling or burning ( signs of peripheral neuropathy). A dose reduction of Paclitaxel 6 mg/ml may be necessary</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you had <strong>previous radiation to your chest </strong>(because it may increase the risk of lung inflammation).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; when severe or persistent diarrhea, with fever and stomach pain occurs during or shortly after treatment with paclitaxel. Your colon could be inflamed (pseudomembranous colitis).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have Kaposi&rsquo;s sarcoma and severe inflammation of the mucous membrane occurs. You may need a lower dose.</p><p>Tell your doctor immediately if any of these apply to you.</p><p>&nbsp;</p><p><strong>Paclitaxel 6 mg/ml should always be administered into veins</strong>. Administration of Paclitaxel 6 mg/ml in the arteries can cause inflammation of the arteries, and you can suffer from pain, swelling, redness and heat.</p><p>&nbsp;</p><p>Take special care before using Paclitaxel 6 mg/ml because the medicine contains alcohol (see section &ldquo;Important information about some of the ingredients of Paclitaxel 6 mg/ml&rdquo;).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p><strong>&nbsp;</strong></p><p>Paclitaxel is not recommended for use in children (under 18 years).</p><p>&nbsp;</p><p><strong>Other medicines and Paclitaxel 6mg/ml</strong></p><p><strong>&nbsp;</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;&nbsp;</p><p>&nbsp;&nbsp; Paclitaxel Injection with food, drink and alcohol: Paclitaxel Injection is unaffected by food and drink.</p><p>&nbsp;</p><p>Speak to your doctor when taking paclitaxel at the same time as any of the following:</p><p>-&nbsp;&nbsp; medicines for treating infections (i.e. antibiotics such erythromycin, rifampicin, etc.; ask your doctor, nurse or pharmacist if you are unsure whether the medicine you are taking is an antibiotic), and including medicines for treating fungal infections (e.g. ketoconazole)</p><p>-&nbsp;&nbsp; medicines used to help you stabilize your mood also sometimes referred to as anti-depressants (e.g. fluoxetine)</p><p>-&nbsp;&nbsp; medicines used to treat seizures (epilepsy) (e.g. carbamazepine, phenytoin)</p><p>-&nbsp;&nbsp; medicines used to help you lower blood lipid levels (e.g. gemfibrozil)</p><p>-&nbsp;&nbsp; medicine used for heartburn or stomach ulcers (e.g. cimetidine)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat HIV and AIDS (e.g. ritonavir, saquinavir, indinavir, nelfinavir, efavirenz, nevirapine)</p><p>-&nbsp;&nbsp; a medicine called clopidogrel used to prevent blood clots.</p><p>&nbsp;</p><p>Paclitaxel 6 mg/ml should be given</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>before cisplatin </strong>(to treat cancer) when used in combination. Your renal function may need to be checked more frequently.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24 hours <strong>after doxorubicin </strong>(to treat cancer), to avoid high level of doxorubicine in your body<strong>. </strong></p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p><strong>Tell your doctor if you are pregnant </strong>or think you may be pregnant before receiving treatment with Paclitaxel 6 mg/ml. If there is a chance that you could become pregnant, <strong>use an effective and safe method of contraception during treatment</strong>. Paclitaxel 6 mg/ml should not be used during pregnancy unless clearly necessary. Female and male patients of fertile age, and/or their partners should use contraceptions for at least 6 months after treatment with paclitaxel.</p><p>This medicine may cause birth defects, therefore, you must not become pregnant during treatment. If &nbsp;&nbsp;pregnancy occurs during treatment, or within the six months after treatment has finished, inform your doctor immediately</p><p>&nbsp;</p><p>Male patients should seek advice regarding cryoconservation of sperm prior to treatment with paclitaxel because of the possibility of infertility. Male patients treated with paclitaxel are advised not to father a child during and up to six months after treatment. As Paclitaxel may have an anti-fertility effect which could be irreversible.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Do not use Paclitaxel 6 mg/ml when you breastfeed. <strong>If you are breast-feeding, tell your doctor</strong>. You have to interrupt breast feeding while you are being treated with Paclitaxel 6 mg/ml. Do not restart breast feeding until your doctor tells you it is safe to do so.</p><p>&nbsp;</p><p>&nbsp;&nbsp; It is not known if paclitaxel passes into breast milk. Because of the possibility of harm to the infant.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p><strong>&nbsp;</strong></p><p>Do not drive immediately after a course of treatment because this medicines contains alcohol.</p><p>&nbsp;</p><p>The quantity of alcohol in this medicine can also impair your ability to use tools and operate machines. As in all cases, you should not drive or use tools or operate machines if you feel dizzy or lightheaded.</p><p>&nbsp;</p><p><strong>Paclitaxel 6 mg/ml contains alcohol and macrogolglycerol ricinoleate.</strong></p><p><strong>&nbsp;</strong></p><p>This medicinal product contains 50 % (by volume) ethanol (alcohol), i.e. up to 20 g per dose, corresponding to 520 ml beer or 210 ml wine per dose. Harmful for those suffering from alcoholism. To be taken into account in pregnant or breast-feeding women, children and high-risk groups such as patients with liver disease or epilepsy.</p><p>&nbsp;</p><p>Paclitaxel may cause side effects such as tiredness (very common) and dizziness (common) that may affect your ability to drive and use machinery. If you experience these symptoms, do not drive or operate machinery until they have fully resolved. If you are given other medicines as part of your treatment, you should ask your doctor for advice on driving and using machines</p><p>&nbsp;</p><p>The quantity of alcohol in this medicinal product can also alter the effect of other medicinal products.</p><p>&nbsp;</p><p>This medicine also contains macrogolglycerol ricinoleate, which can cause severe hypersensitivity reactions. If you are allergic to macrogolglycerol ricinoleate, <strong>talk to your doctor before you receive Paclitaxel 6 mg/ml.</strong></p><p><strong>&nbsp;&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Paclitaxel 6 mg/ml should be used in specialised departments of cancer treatment and should be administered under the supervision of an experienced specialist in cancer treatment.</p><p>&nbsp;</p><p><strong>To minimise allergic reactions, </strong>you will also be given a special premedication (pre-treatment) with several different medicines&nbsp; before each Paclitaxel.&nbsp; These medicines can be given as either tablets or infusion into a vein or both.</p><p>&nbsp;</p><p>The solution for infusion is made by mixing it with glucose solution or in sodium chloride solution. See information for healthcare professionals at the end.</p><p>&nbsp;</p><p>Paclitaxel 6 mg/ml is given by infusion into a vein, through an in-line filter.</p><p>&nbsp;</p><p>Your doctor will decide about the dose of Paclitaxel 6 mg/ml you should have and how many doses you will be given. The amounts (dose) of Paclitaxel 6 mg/ml you will be given is based on your body surface in square meter (m2). and your blood test results. Depending on the type and severity</p><p>&nbsp;</p><p>of the cancer you will receive Paclitaxel 6 mg/ml either alone or in combination with another anticancer agent.</p><p>&nbsp;</p><p>Paclitaxel 6 mg/ml should always be administered into one of your veins over a period of 3 or 24 hours. It is usually given every 2 or 3 weeks, unless your doctor decides otherwise. Your doctor will inform you about the number of courses of Paclitaxel 6 mg/ml you need to receive.</p><p>&nbsp;</p><p>You may feel discomfort or pain if the needle becomes loose or dislodged or, if the solution reaches surrounding tissue. Please inform the doctor or nurse immediately if this occurs.</p><p>&nbsp;</p><p><strong>If you have been given more Paclitaxel 6 mg/ml than you should</strong></p><p><strong>&nbsp;</strong></p><p>There is no known antidote for Paclitaxel 6 mg/ml overdose. You will receive treatment of your symptoms.</p><p>&nbsp;</p><p><strong>If you forget an application of Paclitaxel 6 mg/ml</strong></p><p>&nbsp;</p><p>&nbsp;&nbsp; A double of the dose should not be given if a dose has been forgotten.</p><p><strong>&nbsp;</strong></p><p>Paclitaxel 6 mg/ml needs to be given on a fixed schedule. Be sure to keep all appointments and talk to your doctor if you miss one dose.</p><p>&nbsp;</p><p><strong>If you stop using Paclitaxel 6 mg/ml</strong></p><p><strong>&nbsp;</strong></p><p>Stopping your treatment with Paclitaxel 6 mg/ml may stop the effect on tumour growth. Do not stop treatment with Paclitaxel 6 mg/ml unless you have discussed this with your doctor.</p><p>&nbsp;</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Paclitaxel 6 mg/ml can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Tell your doctor immediately </strong>if you notice any <strong>signs of allergic reactions</strong>. These may include one or more of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flushing,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin reactions,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest tightness,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness or difficulty in breathing,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling.</p><p>These can all be signs of serious side effects.</p><p>&nbsp;</p><p>Tell your doctor immediatly if you</p><p>&sect;&nbsp; have <strong>fever, severe chills, sore throat or mouth ulcers </strong>(signs of bone marrow suppression).</p><p>&sect;&nbsp; have <strong>numbness or weakness of the arms and legs </strong>(signs of peripheral neuropathy)*.</p><p>&sect;&nbsp; develop <strong>severe or persistent diarrhoea</strong>, with fever and stomach pain.</p><p>&nbsp;</p><p>*Can persist beyond 6 months of paclitaxel discontinuation</p><p>&nbsp;</p><p><em><u>Very common (affects more than 1 user in 10)</u></em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections (mainly urinary tract and upper respiratory tract infections). If you have fever or other sign if infection, tell your doctor right away.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tests may show reduced numbers of white and red blood cells and platelets</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever, severe chills, headache, dizziness, tiredness, looking pale, bleeding, bruising more easily than normal</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mild allergic reactions such as hot flushes, skin rash and itching</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injury of peripheral nerves characterised by a creeping sensation, numbness and/or pain in arms and/or legs (all symptoms of peripheral neuropathy)*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea, vomiting, diarrhoea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sore throat or mouth ulcers, sore and red mouth</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss (the majority of cases of hair loss happened less than one month after starting Paclitaxel. When it happens, hair loss is pronounced (over 50%) in the majority of patients)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle or joint pain, cramps</p><p>&nbsp;</p><p>*Can persist beyond 6 months of paclitaxel discontinuation</p><p><em><u>Common (affects 1 to 10 users in 100):</u></em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slower heart rate (pulse)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Transient mild nail and skin changes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reactions at the injection site (local swelling, pain, redness, hardening of tissues, sometimes cellulitis, thickening of the skin [skin fibrosis], death of skin tissue [skin necrosis])</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tests may show severely raised liver enzyme levels (alkaline phosphatase and AST - SGOT ) indicating hepatic function impairment</p><p>&nbsp;</p><p><em><u>Uncommon (affects 1 to 10 users in 1,000):</u></em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shock state as a result of blood poisoning (known as &#39;septic shock&#39;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe hypersensitivity reactions with</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fall in blood pressure, swelling of the face, lips, mouth, tongue or throat, breathlessness and nettle rash; <strong>these reactions require medical treatment</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shivers</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; back pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rapid heart rhythm</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in arms and legs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sweating</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatigue</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the veins</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clots</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; respiratory distress</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast heart rhythm (ventricular tachycardia, tachycardia with bigeminy)</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Palpitations, cardiac dysfunction (AV block)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting (syncope)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart attack</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tests may show raised level of bilirubin (jaundice), a yellow breakdown substance of bile, in the blood</p><p>&nbsp;</p><p><em><u>Rare (affects 1 to 10 users in 10,000):</u></em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood poisoning (sepsis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; peritonitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortage of white blood cells (neutrophilic granulocytes) with fever and increased risk of infection (febrile neutropenia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious and potentially fatal hypersensitivity reaction (anaphylactic reaction)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Effect on nerves that control the muscles, resulting in muscle weakness in arms and legs (motor neuropathy)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breathlessness,interstitial pneumonia, lung fibrosis, pulmonary embolism, dyspnoea, pleural effusion</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bowel obstruction</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bowel perforation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of&nbsp; colon (ischemic colitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the pancreas (pancreatitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching, skin rash/redness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Raised level of creatinine in the blood indicating renal function impairment</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Affection of nerves with feeling of weakness in muscles of arms and legs (motor neuropathy),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pyrexia, dehydration, asthenia, oedema, malaise</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart problems which can cause shortness of breath or ankle swelling.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Very rare (affects less than 1 user in 10,000):</u></em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden disorder in blood forming cells (acute myeloid leukaemia, myelodysplastic syndrome) Serious and potentially fatal hypersensitivity reactions with shock (anaphylactic shock)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite (anorexia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confusion state</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; optic nerve and/or visual disturbances (scintillating scotomata)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hearing loss or reduction (ototoxicity), ringing in the ears (tinnitus), vertigo</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irregular rapid heart rhythm (atrial fibrillation, supraventricular tachycardia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood clot in a blood vessel of abdomen and bowel (mesenteric thrombosis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of colon sometimes with persistent severe diarrhoea (pseudomembranous colitis, neutropenic colitis), dropsy (ascites), oesophagitis, constipation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disturbed liver function (hepatic necrosis hepatic encephalopathy), both with reported cases of fatal outcome</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious hypersensitivity reactions including fever, skin redness, pain in joints and/or inflammation of the eye (Stevens-Johnson syndrome), local peeling of the skin (epidermal necrolysis), redness with irregular red (exudative) spots (erythema multiforme), inflammation of the skin with blisters and peeling (exfoliative dermatitis), urticaria, loose nails (patients on therapy should wear sun protection on hands and feet)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough</p><p>&nbsp;</p><p><em>Not known (cannot be estimated from available data):</em></p><p>&nbsp;</p><p><em>&nbsp;</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tumor lysis syndrome resulting in:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; high levels of blood potassium which can cause abnormal heart rhythm (hyperkalaemia),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; tetany, seizures, mental retardation, movement disorders, emotional instability / agitation / anxiety, pain or weakness in muscles (hypocalcemia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; fatigue, loss of appetite, headache, accumulation of fluid in the limbs and the lungs (renal failure)</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Macular oedema resulting in distort central vision</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Photopsia resulting in the presence of perceived flashes of light.</p><p>Vitreous floaters appearing as spots, threads, or fragments of cobwebs, which float slowly before the observer&#39;s eyes.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of a vein (Phlebitis)</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Symmetrical skin thickening (Scleroderma)</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Systemic lupus erythematosus resulting in fever, malaise, joint pains, myalgias, fatigue, and temporary loss of cognitive abilities</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disseminated intravascular coagulation, or &quot;DIC,&quot; has been reported. This concerns a serious condition that makes people bleed too easily, get blood clots too easily, or both.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness and swelling of the palms of your hands or soles of your feet which may cause your skin to peel</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>Store below 25 ◦C.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label and on the carton after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is paclitaxel. 1 ml concentrate for solution for infusion contains 6 mg paclitaxel.</p><p>A vial of 5 ml contains 30 mg paclitaxel.&nbsp;&nbsp;&nbsp;&nbsp;</p><p>A vial of 16.7 ml contains 100 mg paclitaxel.</p><p>A vial of 25 ml contains 150 mg paclitaxel.</p><p>A vial of 50 ml contains 300 mg paclitaxel.</p><p>A vial of 100 ml contains 600 mg paclitaxel.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are ethanol, anhydrous and polyoxyl castor oil (macrogolglycerol ricinoleate).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Ebetaxel is a clear, colourless to slightly yellow viscous solution in colourless glass vials type I with fluoropolymer-coated halobutyl rubber stopper and aluminium crimp caps.


Each vial contains 30 mg, 100 mg, 150 mg, 300 mg or 600 mg paclitaxel.
Ebetaxel is available in packages with 1, 5, 10 or 20 vials. The 1, 5 or 10 vials are available with or without a protective plastic overwrap (ONCO-SAFE) in a carton.

Not all pack sizes may be marketed.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder&nbsp;</strong></p><p>EBEWE PHARMA GES.M.B.H NFG. KG ,</p><p>UNTERACH,AUSTRIA</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Fareva Unterach GmbH</p><p>&nbsp; 4866 UNTERACH</p><p>&nbsp; AUSTRIA</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                08/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يُعد عقار <strong>باكليتاكسيل</strong> 6 مجم/ مللي لتر أحد العقاقير المضادة للأورام أو المضادة لمرض السرطان. ويمكنه منع انقسام ونمو خلايا السرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم باكليتاكسيل 6 مجم/ مللي لتر لعلاج أنواع مختلفة من السرطان، أي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الثدي</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج سرطان الثدي المبكر بعد الإزالة الجراحية للورم الأساسي بعد العلاج بأنْثراسيكلين وسيكلوفوسفاميد كعلاج إضافي.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كعلاج أول لسرطان الثدي المتقدم أو المنتشر. يُستخدم باكليتاكسيل 6 مجم/ مللي لتر إما بمصاحبة أحد <em>الأَنْثراسيكلينات</em> (على سبيل المثال: دوكسوروبيسين) أو بمصاحبة دواء يُسمى <em>تراستوزوماب</em> (للمرضى الذين لا يناسبهم العلاج بالأنْثراسيكلين والذين يوجد على سطح خلايا السرطان لديهم بروتين يسمى مستقبل عامل نمو البشرة البشري - ٢، انظر نشرة عبوة تراستوزوماب).</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كخط علاج ثان للمرضى الذين لم يستجيبوا للعلاجات القياسية باستخدام الأنْثراسيكلينات، أو الذين لا ينبغي عليهم استخدام هذا العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان المبيض</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كعلاج أول لسرطان المبيض المتقدم، أو للمريضات اللاتي لديهن ورم متبقٍّ يزيد عن 1 سم بعد إجراء الجراحة الأولية بمصاحبة سِيسْبلاتين</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد تجربة العلاج بأدوية قياسية تحتوي على البلاتين ولكن دون جدوى. وكذلك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الرئة المتقدم ذو الخلايا غير الصغيرة:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بمصاحبة سِيسْبلاتين، عندما لا يكون إجراء الجراحة و/ أو العلاج الإشعاعي مناسبين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ساركومة كابوسي المرتبطة بمرض الإيدز:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;عندما تكون قد تمت تجربة علاج آخر (أي، الأنْثراسيكلينات الشحمية) ولكن دون جدوى.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم عقار باكليتاكسيل </strong><strong>6 </strong><strong>مجم</strong><strong>/ </strong><strong>مللي لتر في الحالات التَّالية</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>حساسية</strong> تجاه باكليتاكسيل أو تجاه أي مكون من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم: 6) وخاصة ماكروجول جليسرول ريسينوليت.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مرضعًا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان عدد خلايا الدَّم البيضاء (خلايا العدلات) لديك أقل من 1500 خلية في الميكرولتر (لمرضى السرطان) أو أقل من 1000 خلية في الميكرولتر (لمرضى ساركومة كابوسي). وهذا يحدد من خلال الطاقم الطبي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ساركومة كابوسي وعدوى خطيرة غير منضبطة في الوقت نفسه.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطراب شديد بالكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا انطبق عليك أي مما سبق، <strong>فأخبر طبيبك قبل بدء العلاج بعقار باكليتاكسيل</strong><strong> 6 </strong><strong>مجم</strong><strong>/ </strong><strong>مللي لتر</strong><strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل تناول <strong>إيبيتاكسيل . </strong>ينبغي توخي حذر خاص.</p><p dir="RTL"><strong>للحد من حدوث تفاعلات حساسية،</strong> فإنه سيتم إعطاؤك أدوية أخرى قبل تلقيك عقار <strong>باكليتاكسيل</strong> 6 مجم/ مللي لتر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لاحظت حدوث تفاعلات حساسية ملحوظة (مثل: صعوبة في التَّنفس، ضيق النفس، ضيق الصدر، هبوط في ضغط الدَّم، دوخة، الشعور بدوار الرأس، تفاعلات جلدية مثل: التورم أو الطفح الجلدي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>حمى، قشعريرة شديدة، التهاب الحلق أو قرح بالفم</strong> (علامات الإصابة بكبت النخاع العظمي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من مشاكل بالتَّوصيل القلبي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل خطيرة بالكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من قبل من مشاكل في الذراعين أو الساقين، مثل: التَّنميل، الضعف، الوخز أو الحرقان (علامات على اعتلال الأعصاب الطرفية). فقد يكون من الضَّروري خفض جرعة باكليتاكسيل 6 مجم/ مللي لتر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تعرضت <strong>من قبل لإشعاع بالصدر</strong> (لأنَّ هذا قد يزيد من خطر الإصابة بالالتهاب الرئوي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند حدوث إِسْهال شديد أو مستمر، مع حمى وألم بالمعدة أثناء العلاج بعقار باكليتاكسيل أو بعده بوقت قصير. فقد يلتهب القولون لديك (الْتِهابُ القولونِ الغِشائِيُّ الكاذِب).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ساركومة كابوسي وحدث التهاب شديد بالأغشية المخاطية. فقد تحتاج إلى تلقى جرعة أقل.</p><p dir="RTL">أخبر طبيبك فورًا إذا انطبق عليك أي مما سبق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب أن يتم دائمًا إعطاء باكليتاكسيل </strong><strong>6 </strong><strong>مجم</strong><strong>/ </strong><strong>مللي لتر في الأوردة</strong><strong>.</strong> فإعطاء باكليتاكسيل 6 مجم/ مللي لتر في الشرايين من شأنه أن يُسبب التهابًا بالشرايين، وقد تعاني جراء ذلك من ألم، تورم، احمرار وإحساس بالحرارة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي توخي حذر خاص قبل استخدام باكليتاكسيل 6 مجم/ مللي لتر؛ لأنَّ الدَّواء يحتوي على كحول (انظر قسم: &quot;معلومات هامة حول بعض مكونات عقار باكليتاكسيل 6 مجم/ مللي لتر&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا يُوصى باستخدام باكليتاكسيل في الأطفال (الأقل من 18 عامًا).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>استخدام أدوية أخرى مع عقار باكليتاكسيل</strong><strong> </strong><strong>6 </strong><strong>مجم</strong><strong>/ </strong><strong>مللي لتر</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى.</p><p dir="RTL">استخدام باكليتاكسيل حُقن مع الأطعمة والمشروبات والكحوليات: لا يتأثر باكليتاكسيل حُقن بالطعام والشراب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تتلقى باكليتاكسيل في الوقت نفسه مع أي مما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج العدوى (أي، مضادات حيوية مثل: إريثروميسين، رِيفامبيسِين وما إلى ذلك؛ اسأل طبيبك أو الممرض(ة) أو الصيدلي الخاص بك إذا لم تكن متأكدًا مما إذا كان الدَّواء الذي تتناوله مضادًّا حيويًّا أم لا)، بما في ذلك أدوية لعلاج العدوى الفطرية (مثل: كيتوكونازول).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تستخدم لمساعدتك على استقرار الحالة المزاجية والتي يُشار إليها أيضًا في بعض الأحيان بكلمة مضادات الاكتئاب (مثل: فلوكسيتين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستخدم لعلاج النوبات التشنجية (الصرع) (مثل: كَرْبامازِيبين، فينيتوين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تُستخدم لمساعدتك على خفض مستويات الدهون في الدَّم (مثل: جيمفيبروزيل).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تستخدم لعلاج الحموضة (حُرْقَةُ الفُؤاد) أو قرح المعدة (مثل سيميتيدين<em>).</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تستخدم لعلاج فيروس نقص المناعة البشري &quot;HIV&quot; والإيدز (مثل ريتونافير، ساكوينافير، إندينافير، نيلفينافير، إيفافيرينز، نيفيرابين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء يُسمى كلوبيدوجريل يُستخدم لمنع تكون جلطات الدَّم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب إعطاء باكليتاكسيل 6 مجم/ مللي لتر</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قبل سِيسْبلاتين</strong><strong>)</strong> لعلاج السرطان ( عند استخدام العقارين بشكل متصاحب. وربما ينبغي فحص وظائف الكلى لديك بشكل أكثر تكرارًا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>بعد</strong> مرور 24 ساعة من إعطاء <strong>دوكسوروبيسين</strong> (لعلاج السرطان)، تفاديًا لارتفاع مستوى دوكسوروبيسين لديك في الجسم.</p><p dir="RTL"><strong>&nbsp;الحمل والرَّضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو مرضعًا، أو تعتقدين أنكِ حامل أو تخططين لذلك، فاستشيري طبيبك أو الصيدلي الخاص بك قبل تلقي هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الحمل</u></p><p dir="RTL"><strong>أخبري طبيبكِ إذا كنتِ حاملًا</strong>، أو تعتقدين أنكِ قد تكونين حاملًا قبل تلقي العلاج بعقار باكليتاكسيل 6 مجم/ مللي لتر. وإذا كان هناك احتمال لإمكانية حدوث حمل، فيجب عليكِ <strong>استخدام وسيلة فعالة وآمنة لمنع الحمل أثناء فترة العلاج</strong><strong>.</strong> يجب عدم استخدام باكليتاكسيل 6 مجم/ مللي لتر أثناء الحمل ما لم تكن هناك ضرورة واضحة لذلك. ويجب على الإناث والذكور في سن الخصوبة، و/ أو أزواجهم/ زوجاتهم استخدام وسائل منع الحمل لمدة لا تقل عن 6 أشهر بعد العلاج بعقار باكليتاكسيل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يسبب هذا الدَّواء عيوبًا خلقية، وبالتَّالي، يجب عليكِ عدم الحمل أثناء العلاج. إذا حدث حمل أثناء العلاج، أو خلال ستة أشهر بعد انتهاء العلاج، أخبري طبيبكِ على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي على المرضى من الذكور أن يطلبوا الاستشارة فيما يتعلق بحفظ الحيوانات المنوية عن طريق التبريد الشديد قبل العلاج بعقار باكليتاكسيل؛ نظرًا لاحتمالية حدوث عقم. ينصح المرضى الذكور الذين عولجوا بعقار <strong>إيبيتاكسيل</strong> بعدم الإنجاب خلال فترة تصل إلى ستة أشهر بعد العلاج. كما باكليتاكسيل قد يكون لها تأثير مضاد للخصوبة الذي يمكن أن يكون لا رجعة فيه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">لا تستخدمي عقار <strong>باكليتاكسيل</strong> 6 مجم/ مللي لتر أثناء ممارستك للرضاعة الطبيعية. <strong>أخبري طبيبكِ إذا كنتِ مرضعًا</strong><strong>.</strong> ويجب أن تتوقفي عن ممارسة الرضاعة الطبيعية أثناء علاجك بعقار باكليتاكسيل 6 مجم/ مللي لتر. لا تعيدي بدء الرضاعة الطبيعيَّة حتى يخبرك طبيبك أنه من الآمن فعل ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من غير المعروف ما إذا كان باكليتاكسيل يمر إلى لبن الأم أم لا. نظرًا لاحتمالية وجود ضرر على الطفل الرضيع.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا ينبغي ممارسة القيادة مباشرةً بعد تلقي دورة العلاج؛ لأنَّ هذا الدَّواء يحتوي على كحول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن لكمية الكحول الموجودة في هذا الدَّواء أيضًا أن تضعف من قدرتك على استخدام الأدوات وتشغيل الآلات. وفي كل الحالات، فإنَّه يجب عدم ممارسة القيادة أو استخدام الأدوات أو تشغيل الآلات إذا كنت تشعر بدوخة أو دوار.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي عقار باكليتاكسيل</strong><strong> 6 </strong><strong>مجم</strong><strong>/ </strong><strong>مللي لتر على كحول وماكروجول جليسرول ريسينوليت</strong><strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يحتوي هذا المنتج الدَّوائي على 50٪ (من حجمه) إيثانول (كحول)، أي ما يصل إلى 20 جرامًا لكل جرعة. ويكون هذا ضارًّا بالنسبة لأولئك الذين يعانون من إدمان الكحوليات. ويجب مراعاة ذلك بالنسبة للسيدات من الحوامل أو المرضعات والأطفال والمجموعات المعرضين لخطورة مرتفعة مثل المرضى الذين يعانون من أمراض بالكبد أو الصَّرع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يسبب باكليتاكسيل آثارًا جانبية مثل التَّعب (شائع جدًّا) ودوخة (شائعة) وهو ما قد يُؤثر في قدرتك على القيادة واستخدام الآلات. إذا تعرضت للإصابة بهذه الأعراض، فلا تمارس القيادة أو تشغيل الآلات حتى تزول تمامًا. إذا تم إعطاؤك أدوية أخرى كجزء من علاجك، يجب عليك أن تطلب من طبيبك المشورة بشأن القيادة واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن لكمية الكحول الموجودة في هذا المنتج الدَّوائي أن تغير أيضًا من تأثير المنتجات الدَّوائية الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا الدَّواء أيضًا على ماكروجول جليسرول ريسينوليت، والذي من شأنه أن يُسبب تفاعلات فرط حساسية شديدة. إذا كنت تعاني من حساسية تجاه ماكروجول جليسرول ريسينوليت، <strong>فتحدَّث إلى طبيبك قبل أن تتلقى عقار باكليتاكسيل</strong><strong> 6 </strong><strong>مجم</strong><strong>/ </strong><strong>مللي لتر</strong><strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">جب استعمال باكليتاكسيل 6 مجم/ مللي لتر في الأقسام المتخصصة لعلاج السرطان، ويجب إعطاؤه تحت إشراف أخصائي يتمتع بخبرة في علاج السرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للحد من حدوث تفاعلات حساسية،</strong> فإنه سيتم أيضًا إعطاؤك علاجًا تحضيريًّا خاصًّا (قبل العلاج) مع عدة أدوية مختلفة قبل كل مرة يتم فيها إعطاؤك عقار باكليتاكسيل. ومن الممكن أن يتم إعطاء هذه الأدوية إما في صورة أقراص أو تسريب في الوريد أو كليهما.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم تحضير محلول التَّسريب من خلال خلطه مع محلول جلوكوز أو في محلول كلوريد الصوديوم. انظر المعلومات الخاصَّة بأخصائيي الرعاية الصحية في النهاية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم إعطاء عقار باكليتاكسيل 6 مجم/ مللي لتر عن طريق التَّسريب في الوريد، من خلال مرشح داخلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقرر طبيبك جرعة عقار<strong> باكليتاكسيل</strong> 6 مجم/ مللي لتر التي يجب أن تتلقاها وعدد الجرعات التي سوف يتم إعطاؤها لك. وتعتمد كميات (جرعة) عقار باكليتاكسيل 6 مجم/ مللي لتر التي ستُعطى لك على مساحة سطح الجسم لديك بالمتر المربع (م<sup>2</sup>). وكذلك نتائج اختبارات الدَّم الخاصة بك. بحسب نوع ودرجة شدة السرطان فإنه سيتم تلقيك عقار باكليتاكسيل 6 مجم/ مللي لتر إما بمفرده أو بمصاحبة أحد مضادات السرطان الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن يتم دائمًا إعطاء عقار باكليتاكسيل 6 مجم/ مللي لتر في أحد الأوردة لديك على مدار فترة 3 ساعات أو 24 ساعة. ويتم إعطاؤه عادةً كل أسبوعين أو 3 أسابيع، ما لم يقرر طبيبك خلاف ذلك. سيخبرك طبيبك بعدد دورات العلاج بعقار باكليتاكسيل 6 مجم/ مللي لتر التي تحتاج إلى تلقيها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تشعر بانزعاج أو ألم إذا أصبحت الإبرة غير محكمة أو تم خلعها أو إذا وصل المحلول إلى النسيج المحيط. ينبغي أن تخبر الطبيب أو الممرض(ة) فورًا إذا حدث ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تم إعطاؤك كمية أكثر مما يجب من عقار باكليتاكسيل</strong><strong> 6 </strong><strong>مجم</strong><strong>/ </strong><strong>مللي لتر</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا يُوجَد ترياق معروف للجرعة الزَّائدة من عقار <strong>باكليتاكسيل</strong> 6 مجم/ مللي لتر. ستتلقى علاجًا للأعراض التي تعاني منها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أغفلت استخدام عقار باكليتاكسيل</strong><strong> 6 </strong><strong>مجم</strong><strong>/ </strong><strong>مللي لتر</strong></p><p dir="RTL">يجب عدم إعطاء جرعة مضاعفة في حالة إغفال إحدى الجرعات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">ينبغي إعطاء عقار<strong> باكليتاكسيل</strong> 6 مجم/ مللي لتر طبقًا لجدول مواعيد ثابت. تأكد من الحفاظ على حضور كل المواعيد والتَّحدث مع طبيبك إذا أغفلت إحدى الجرعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استخدام عقار باكليتاكسيل</strong><strong> 6 </strong><strong>مجم</strong><strong>/ </strong><strong>مللي لتر</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إيقاف علاجك بعقار<strong> باكليتاكسيل</strong> 6 مجم/ مللي لتر من شأنه أن يوقف التَّأثير على نمو الورم. ينبغي أَلَّا توقف العلاج بعقار<strong> باكليتاكسيل</strong> 6 مجم/ مللي لتر إلا إذا ناقشت هذا الأمر مع طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا المنتج، فاستشر طبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كافة الأدوية، قد يُسبب عقار<strong> باكليتاكسيل</strong> 6 مجم/ مللي لتر آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك فورًا</strong> إذا لاحظت أيًّا من <strong>علامات تفاعلات الحساسية</strong>. وهي قد تشمل واحدة أو أكثر مما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التفاعلات الجلدية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيقًا في الصدر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة أو ضيقًا في التَّنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورمًا.</p><p dir="RTL">هذه كلها يمكن أن تكون علامات لآثار جانبية خطيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب عليك إخبار طبيبك فورًا في الحالات الآتية</strong><strong>:</strong></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>حمى، قشعريرة شديدة، التهاب الحلق أو قرح بالفم</strong> (علامات الإصابة بكبت النخاع العظمي).</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>تنميل أو ضعف في الذراعين والساقين</strong> (علامات الإصابة باعتلال الأعصاب الطرفية)*.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصبت <strong>بإِسْهال شديد أو مستمر</strong>، مع حمى وألم بالمعدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">* يمكن أن تستمره بعد 6 أشهر من التوقف عن استخدام باكليتاكسيل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>شائعة جدًّا </u></em><em><u>(</u></em><em><u>تُؤثر على أكثر من </u></em><em><u>1 </u></em><em><u>من بين كل </u></em><em><u>10 </u></em><em><u>مستخدمين</u></em><em><u>)</u></em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى (وبالأخص عدوى المسالك البولية وعدوى الجهاز التَّنفسي العلوي). أخبر طبيبك على الفور إذا أصبت بحمى أو ظهرت عليك علامة أخرى من علامات العدوى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق بالتَّنفس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تُظهر الاختبارات انخفاضًا في أعداد خلايا الدَّم الحمراء والبيضاء والصفائح الدَّموية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى، قشعريرة شديدة، صداع، دوخة، تعب، شحوب، نزيف، سهولة الإصابة بكدمات بشكل أكثر من المعتاد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية طفيفة مثل: الهبات الساخنة والطفح الجلدي والحكة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصابة في الأعصاب الطرفية تتسم بإحساس الخدر، تنميل و/ أو ألم في الذراعين و/ أو الساقين (كل أعراض الإصابة باعتلال الأعصاب الطرفية)*.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدَّم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان، قيء، إسهال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحلق أو قُرَح الفم، التهاب الفم واحمراره.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر (حدثت معظم حالات تساقط الشعر بعد أقل من شهر واحد من بدء عقار باكليتاكسيل. وعندما يحدث تساقط الشعر، فإنه يكون شديدًا (بنسبة تتجاوز 50٪) لدى أغلب المرضى).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمفاصل أو العضلات، تقلصات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">* يمكن أن تستمره بعد 6 أشهر من التوقف عن استخدام باكليتاكسيل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>شائعة </u></em><em><u>(</u></em><em><u>تؤثر على </u></em><em><u>1 </u></em><em><u>إلى </u></em><em><u>10 </u></em><em><u>مستخدمين من بين كل </u></em><em><u>100 </u></em><em><u>مستخدم</u></em><em><u>):</u></em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تباطؤ مُعدَّل ضربات القلب (النبض).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات عابرة وخفيفة في الأظافر والجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات بموضع الحقن (تورم موضعي، ألم، احمرار، تصلب الأنسجة، التِهاب النّسِيجِ الخلوي في بعض الأحيان، سماكة الجلد [تليف الجلد]، موت نسيج الجلد [نخر الجلد]).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تُظهر الاختبارات ارتفاعات شديدة في مستويات إنزيمات الكبد (الفوُسْفاتيز القَلَوِي وناقِلَة الأَمينِ الأسبارتية -ناقلة أمين الجلوتاميك أوكسالو- أسيتيك) مما يُشير إلى قصور وظائف الكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>غير شائعة </u></em><em><u>(</u></em><em><u>تُؤثر على </u></em><em><u>1 </u></em><em><u>إلى </u></em><em><u>10 </u></em><em><u>مستخدمين من كل </u></em><em><u>1000 </u></em><em><u>مستخدم</u></em><em><u>):</u></em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة صدمة نتيجة تسمم الدَّم (تعرف باسم: &quot;الصدمة الإنتانية&quot;).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات فرط حساسية شديدة مع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبوط في ضغط الدَّم، تورم الوجه، الشفتين، الفم، اللسان، أو الحَلْق، عُسْر التَّنَفُّس وطفح القراص؛ <strong>تتطلب هذه التفاعلات علاجًا طبيًّا</strong><strong>.</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتجاف.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام الظهر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالصدر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نظم قلبي سريع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الذراعين والساقين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إرهاق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدَّم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوردة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكون جلطات الدَّم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التَّنفس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع النظم القلبي (تسرُّع ضربات القَلْب البطيني، تسارع ضربات القَلْب مع توأمية النبض).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفقان، اختلال وظائف القلب (الإحصار الأذيني البطيني).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء (غشي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تُظهر الاختبارات ارتفاعًا في مستوى البِيليروبين (يرقان)، وهي مادة متحللة صفراء من المرارة، في الدَّم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>نادرة </u></em><em><u>(</u></em><em><u>تُؤثر على </u></em><em><u>1 </u></em><em><u>إلى </u></em><em><u>10 </u></em><em><u>مستخدمين من بين كل </u></em><em><u>10000 </u></em><em><u>مستخدم</u></em><em><u>):</u></em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسمم دموي (تعفن الدَّم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الْتِهاب الصِّفاق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص عدد خلايا الدَّم البيضاء (خلايا العدلات المحببة) مع حمى وزيادة خطر العدوى (قلة خلايا العَدِلات الحموي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل فرط حساسية خطير وربما يكون مميتًا (تفاعل تَأَقِيّ).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التَّأثير على الأعصاب التي تتحكم في العضلات، مما يُؤدي إلى ضعف العضلات في الذراعين والساقين (اعتلال الأعصاب الحركية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عُسْرُ التَّنَفُّس، التهاب رئوي خلالي، تليف رئوي، انصمام رئوي، ضيق التنفس، انصباب بلوري.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد الأمعاء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انثقاب الأمعاء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القولون (الْتِهاب القولونِ الإِقْفارِيُّ).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة، طفح جلدي/ احمرار.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع في مستويات الكرياتينين بالدَّم مما يُشير إلى قصور وظائف الكلى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التَّأثير على الأعصاب مع شعور بالضعف في عضلات الذراعين والساقين (اعتلال الأعصاب الحركية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة الحرارة (حمى)، جفاف، وهن، وذمة، تَوَعُّك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل قلبية قد تُسبب ضيق التَّنفس أو تورم الكاحل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>نادرة جدًّا </u></em><em><u>(</u></em><em><u>تُؤثر على أقل من مستخدم واحد من بين كل </u></em><em><u>10000 </u></em><em><u>مستخدم</u></em><em><u>):</u></em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب مفاجئ في خلايا تكون الدم (سرطان الدَّم النخاعي الحاد، متلازمة خلل التنسج النخاعي) تفاعلات فرط حساسية خطيرة وربما تكون مميتة مع صدمة (صدمة تأقية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة من الارتباك/ الالتباس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات العصب البصري و/ أو اضطرابات الرؤية (العتمة الوامضة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان السمع أو ضعف السمع (السمية الأذنية)، طنين في الأذنين، دُوار.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع وعدم انتظام نظم القلب (الرجفان الأذيني وتسرُّع ضربات القَلْب فوق البطيني).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجلط الدَّم في أحد الأوعية الدَّموية للبطن والأمعاء (الخثار المساريقي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القولون المصحوب في بعض الأحيان بإسهال شديد ومستمر (الْتِهابُ القولونِ الغِشائِيّ الكاذِب، التهاب القولون الناتج عن قلة خلايا العدلات)، خَزَب (استسقاء)، التهاب المريء، إمساك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب وظائف الكبد (النخر الكبدي والاعتلال الدماغي الكبدي، كلاهما كان مع حالات عواقب مميتة تم رصدها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات فرط حساسية خطيرة تشمل: الحمى، احمرار الجلد، ألمًا بالمفاصل و/ أو التهاب العينين (متلازمة ستيفنز جونسون)، تقشرًا موضعيًّا بالجلد (تَقَشُّر الأَنْسِجَةِ المُتَمَوِّتَةِ البَشْرَوِيَّةِ)، احمرارًا مصحوبًا ببقع (نضحية) حمراء غير منتظمة (احمرارًا متعدد الأشكال)، التهاب الجلد المصحوب ببثور وتقشر (التهاب الجلد التقشري)، أرتكاريا، تخلخل الأظافر (يجب على المرضى الخاضعين للعلاج ارتداء وسائل للوقاية من الشمس على اليدين والقدمين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>غير معروفة </em><em>(</em><em>لا يمكن تقديرها من واقع البيانات المتاحة</em><em>):</em></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">متلازمة انحلال الورم التي تُؤدي إلى:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات البوتاسيوم في الدَّم مما قد يُؤدي إلى اضطراب نظم القلب (فرط بوتاسيوم الدَّم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكزز، نوبات تشنجية، تأخر عقلي، اضطرابات الحركة، عدم الاستقرار العاطفي/ هِياج/ قلق، ألم أو ضعف في العضلات (نَقْص كالسيومِ الدَّم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إرهاق، فقدان الشهية، صداع، تراكم السوائل في الأطراف والرئتين (فشل كلوي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وذمة بقعية تؤدي إلى تشوه الرؤية المركزية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ترائي الومضات الذي يُؤدي إلى وجود ومضات ضوء محسوسة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عوائم بالجسم الزجاجي للعين تظهر على هيئة بقع، خيوط، أو أجزاء لنسيج العنكبوت، والتي تعوم ببطء أمام أعين المشاهد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الوريد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سماكة الجلد المتماثلة (تصلب الجلد).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذِّئْبَة الحُمَامِيَّة الجَهازِيَّة التي تُؤدي إلى الإصابة بحمى، تَوَعُّك، ألم بالمفاصل، آلام بالعضلات، إرهاق وفقدان مؤقت للقدرات المعرفية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم الإبلاغ عن حالات من التجلّط المُنْتَثِر داخِل الأَوعِيَة الدَّموية. وهذا يتعلق بحالة خطيرة تجعل الأشخاص ينزفون بسهولة شديدة، أو يصابون بجلطات دموية بسهولة شديدة، أو كليهما.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار وتورم راحتي يديك أو باطن قدميك مما قد يتسبب في تقشير بشرتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">احتفظ بالزجاجة داخل العبوة الكرتونية الخارجية لحمايتها من الضوء.</p><p dir="RTL">يخزن في درجة حرارة أقل من 25 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد انتهاء تاريخ الصلاحية المدون على الملصق وعلى العبوة الكرتونية بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم التَّخلص من الأدوية عن طريق مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تعد بحاجة إليها. تُساعد هذه الإجراءات في الحفاظ على البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong>المادة الفعالة هي باكليتاكسيل. يحتوي كل 1 مللي لتر من المادة المُركَّزة لإعداد محلول للتَّسريب على 6 مجم من باكليتاكسيل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي الزجاجة الواحدة سعة 5 مللي لتر على 30 مجم من باكليتاكسيل.</p><p dir="RTL">تحتوي الزجاجة الواحدة سعة 16.7 مللي لتر على 100 مجم من باكليتاكسيل.</p><p dir="RTL">&nbsp;تحتوي الزجاجة الواحدة سعة 25 مللي لتر على 150 مجم من باكليتاكسيل.</p><p dir="RTL">تحتوي الزجاجة الواحدة سعة 50 مللي لتر على 300 مجم من باكليتاكسيل.</p><p dir="RTL">تحتوي الزجاجة الواحدة سعة 100 مللي لتر على 600 مجم من باكليتاكسيل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-المكونات الأخرى هي إيثانول، زيت خروع بوليوكسيل وغير مائي (ماكروجول جليسرول ريسينوليت).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إيبيتاكسيل هو محلول لزج شفاف عديم اللون إلى أصفر قليلاً في قوارير زجاجية عديمة اللون من النوع الأول مع سدادة مطاطية مطلية بالفلوروبوليمر وأغطية تجعيد من الألومنيوم .</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل زجاجة على 30 مجم أو 100 مجم أو 150 مجم أو 300 مجم أو 600 مجم من باكليتاكسيل.</p><p dir="RTL">يتوفر عقار إيبيتاكسيل 6 مجم/ مللي لترفي عبوات بها 1 , 5 , 10 أو 20 زجاجة . وتتوفر الزجاجة الواحدة &nbsp;أو 5 أو 10 أو 20 مع أو بدون غلاف بلاستيكي واقٍ (ONCO-SAFE) في عبوة كرتون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التسويق</strong></p><p dir="RTL">شركة إيبيفيه فارما المحدودة . NFG. شراكة محدودة</p><p dir="RTL">أونتراخ،</p><p dir="RTL">النمسا</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p><strong>جهة التَّصنيع</strong></p><p>&nbsp;شركة فاريفا أونتراخ المحدودة</p><p dir="RTL">&nbsp;أونتراخ، النمسا4866</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            08/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ebetaxel 6 mg/ml concentrate for solution for infusion


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml concentrate for solution for infusion contains 6 mg paclitaxel. 
Each 5 ml vial contains 30 mg paclitaxel.
Each 16.7 ml vial contains 100 mg paclitaxel.
Each 25 ml vial contains 150 mg paclitaxel. 
Each 50 ml vial contains 300 mg paclitaxel. 
Each 100 ml vial contains 600 mg paclitaxel.


Excipients with known effect:
 Ethanol, anhydrous (401,7 mg/ml),polyoxyl castor oil (macrogolglycerol ricinoleate) (522,4 mg/ml) For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion.

Paclitaxel 6 mg/ml is a clear, colourless to slightly yellow viscous solution.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Ovarian carcinoma</u>: in the first-line chemotherapy of ovarian cancer, Paclitaxel 6 mg/ml is indicated for the treatment of patients with advanced carcinoma of the ovary or with residual disease (&gt; 1 cm) after initial laparotomy, in combination with cisplatin.</p><p>&nbsp;</p><p>In the second-line chemotherapy of ovarian cancer, Paclitaxel 6 mg/ml is indicated for the treatment of metastatic carcinoma of the ovary after failure of standard, platinum containing therapy.</p><p>&nbsp;</p><p><u>Breast carcinoma</u>: in the adjuvant setting, Paclitaxel 6 mg/ml is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and cyclophosphamide (AC) therapy.</p><p>Adjuvant treatment with Paclitaxel 6 mg/ml should be regarded as an alternative to extended AC therapy.</p><p>&nbsp;</p><p>Paclitaxel 6 mg/ml is indicated for the initial treatment of locally advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracycline therapy is suitable, or in combination with trastuzumab, in patients who over-express HER-2 at a 3+ level as determined by immunohistochemistry and for whom an anthracycline is not suitable (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p>&nbsp;</p><p>As a single agent, Paclitaxel 6 mg/ml is indicated for the treatment of metastatic carcinoma of the breast in patients who have failed, or are not candidates for standard, anthracycline containing therapy.</p><p>&nbsp;</p><p><u>Advanced non-small cell lung carcinoma</u>: Paclitaxel 6 mg/ml, in combination with cisplatin, is indicated for the treatment of non-small cell lung carcinoma (NSCLC) in patients who are not candidates for potentially curative surgery and/or radiation therapy.</p><p>&nbsp;</p><p><u>AIDS-related Kaposi&rsquo;s sarcoma</u>: Paclitaxel 6 mg/ml is indicated for the treatment of patients with advanced AIDS-related Kaposi&rsquo;s sarcoma (KS) who have failed prior liposomal anthracycline therapy.</p><p>&nbsp;</p><p>Limited efficacy data supports this indication, a summary of the relevant studies is shown in section 5.1.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Paclitaxel 6 mg/ml should only be administrated under the supervision of a qualified oncologist in units specialised in the administration of cytotoxic agents (see section 6.6).</p><p>&nbsp;</p><p>All patients must be premedicated with corticosteroids, antihistamines, and H2 antagonists prior to Paclitaxel 6 mg/ml, e.g:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal Product</strong></p></td><td style="vertical-align:top"><p><strong>Dose</strong></p></td><td style="vertical-align:top"><p><strong>Administration prior to Paclitaxel 6 mg/ml</strong></p></td></tr><tr><td style="vertical-align:top"><p>dexamethasone</p></td><td style="vertical-align:top"><p>20 mg oral* or IV</p></td><td style="vertical-align:top"><p>For oral administration: approximately 12 and 6 hours or for IV administration: 30 to 60 min</p></td></tr><tr><td style="vertical-align:top"><p>diphenhydramine**</p></td><td style="vertical-align:top"><p>50 mg IV</p></td><td style="vertical-align:top"><p>30 to 60 min</p></td></tr><tr><td style="vertical-align:top"><p>cimetidine or ranitidine</p></td><td style="vertical-align:top"><p>300 mg IV</p><p>50 mg IV</p></td><td style="vertical-align:top"><p>30 to 60 min</p></td></tr></tbody></table><p>&nbsp;</p><p>* 8-20 mg for KS patients</p><p>** or an equivalent antihistamine e.g. chlorpheniramine</p><p>&nbsp;</p><p>For instructions on dilution of the product before administration, see section 6.6. Paclitaxel 6 mg/ml should be administered intravenously through an in-line filter with a microporous membrane</p><p>&le; 0.22 &mu;m (see section 6.6).</p><p>&nbsp;</p><p><u>First-line chemotherapy of ovarian carcinoma</u>: although other dosage regimens are under investigation, a combination regimen of Paclitaxel 6 mg/ml and cisplatin is recommended. According to duration of infusion, two doses of Paclitaxel 6 mg/ml are recommended: paclitaxel 175 mg/m2 administered intravenously over 3 hours, followed by cisplatin at a dose of 75 mg/m2 every</p><p>three weeks or paclitaxel 135 mg/m&sup2;, in a 24-hour infusion, followed by cisplatin 75 mg/m&sup2;, with a 3 week interval between courses (see section 5.1).</p><p>&nbsp;</p><p><u>Second-line chemotherapy of ovarian carcinoma</u>: the recommended dose of paclitaxel is 175 mg/m&sup2; administered over a period of 3 hours, with a 3 week interval between courses.</p><p>&nbsp;</p><p><u>Adjuvant chemotherapy in breast carcinoma</u>: the recommended dose of paclitaxel is 175 mg/m&sup2; administered over a period of 3 hours every 3 weeks for four courses, following AC therapy.</p><p>&nbsp;</p><p><u>First-line chemotherapy of breast carcinoma</u>: when used in combination with doxorubicin (50 mg/m&sup2;), Paclitaxel 6 mg/ml should be administered 24 hours after doxorubicin. The recommended dose of</p><p>&nbsp;</p><p>paclitaxel is 220 mg/m&sup2; administered intravenously over a period of 3 hours, with a 3-week interval between courses (see sections 4.5 and 5.1).</p><p>When used in combination with trastuzumab, the recommended dose of paclitaxel is 175 mg/m&sup2; administered intravenously over a period of 3 hours, with a 3-week interval between courses (see section 5.1). Paclitaxel 6 mg/ml infusion may be started the day following the first dose of trastuzumab or immediately after the subsequent doses of trastuzumab if the preceding dose of trastuzumab was well tolerated (for detailed trastuzumab posology see the Summary of Product Characteristics of trastuzumab).</p><p>&nbsp;</p><p><u>Second-line chemotherapy of breast carcinoma</u>: the recommended dose of paclitaxel is 175 mg/m&sup2; administered over a period of 3 hours, with a 3-week interval between courses.</p><p>&nbsp;</p><p><u>Treatment of advanced NSCLC</u>: the recommended dose of paclitaxel is 175 mg/m&sup2; administered over a period of 3 hours, followed by cisplatin 80 mg/m&sup2;, with a 3 week interval between courses.</p><p>&nbsp;</p><p><u>Treatment of AIDS-related KS</u><strong>: </strong>the recommended dose of paclitaxel is 100 mg/m&sup2; administered as a 3-hour intravenous infusion every two weeks.</p><p>&nbsp;</p><p>Subsequent doses of Paclitaxel 6 mg/ml should be administered according to individual patient tolerance.</p><p>&nbsp;</p><p>Paclitaxel 6 mg/ml should not be readministered until the neutrophil count is &ge; 1,500/mm&sup3;&nbsp;&nbsp; (&ge; 1,000/mm&sup3; for KS patients) and the platelet count is &ge; 100,000/mm&sup3; (&ge; 75,000/mm&sup3; for KS</p><p>patients). Patients who experience severe neutropenia (neutrophil count &lt; 500/mm&sup3; for a week or longer) or severe peripheral neuropathy should receive a dose reduction of 20% for subsequent courses (25% for KS patients) (see section 4.4).</p><p>&nbsp;</p><p><u>Patients with hepatic impairment</u>: inadequate data are available to recommend dosage alterations in patients with mild to moderate hepatic impairments (see sections 4.4 and 5.2). Patients with severe hepatic impairment should not be treated with paclitaxel.</p><p>&nbsp;</p><p><u>Paediatric population</u>: Paclitaxel is not recommended for use in children below 18 years due to lack of data on safety and efficacy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1, especially macrogolglycerol ricinoleate (see section 4.4).

Paclitaxel should not be used in patients with baseline neutrophils < 1,500/mm³ (< 1,000/mm³ for KS patients).

Patients with severe hepatic impairment must not be treated with paclitaxel (see 4.4) Paclitaxel contraindicated during lactation (see section 4.6).
In KS, paclitaxel is also contraindicated in patients with concurrent, serious, uncontrolled infections.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Paclitaxel 6 mg/ml should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Since significant hypersensitivity reactions may occur, appropriate supportive equipment should be available.</p><p>&nbsp;</p><p>&nbsp;</p><p>Given the possibility of extravasation, it is advisable to closely monitor the infusion site for possible infiltration during drug administration.</p><p>&nbsp;</p><p>Patients must be pretreated with corticosteroids, antihistamines and H2 antagonists (see section 4.2). Paclitaxel 6 mg/ml should be given before cisplatin when used in combination (see section 4.5).</p><p><em>Significant hypersensitivity reactions </em>characterised by dyspnoea and hypotension requiring treatment, angioedema and generalised urticaria have occurred in &lt; 1% of patients receiving paclitaxel after adequate premedication. These reactions are probably histamine-mediated. In the case of severe hypersensitivity reactions, Paclitaxel 6 mg/ml infusion should be discontinued immediately, symptomatic therapy should be initiated and the patient should not be rechallenged with the medicinal product.</p><p>&nbsp;</p><p><em>Bone marrow suppression </em>(primarily neutropenia) is the dose-limiting toxicity. Frequent monitoring of blood counts should be instituted. Patients should not be retreated until neutrophils recover to</p><p>&ge; 1,500/mm&sup3; (&ge; 1,000/mm&sup3; for KS patients) and platelets recover to &ge; 100,000/mm&sup3; (&ge; 75,000/mm&sup3; for KS patients). In the KS clinical study, the majority of patients were receiving granulocyte colony stimulating factor (G-CSF).</p><p>&nbsp;</p><p><em>Patients with hepatic impairment </em>may be at increased risk of toxicity, particularly Grade 3-4 myelosuppression. There is no evidence that the toxicity of paclitaxel is increased when given as a 3-hour infusion to patients with mildly abnormal liver function. When paclitaxel is given as a longer infusion, increased myelosuppression may be seen in patients with moderate to severe hepatic impairment. Patients should be monitored closely for the development of profound myelosuppression (see section 4.2). Inadequate data are available to recommend dosage alterations in patients with mild to moderate hepatic impairments (see section 5.2).</p><p>No data are available for patients with severe baseline cholestasis. Patients with severe hepatic impairment must not be treated with paclitaxel.</p><p>&nbsp;</p><p><em>Severe cardiac conduction abnormalities </em>have been reported rarely with single agent paclitaxel. If patients develop significant conduction abnormalities during paclitaxel administration, appropriate therapy should be administered and continuous cardiac monitoring should be performed during subsequent therapy with paclitaxel. Hypotension, hypertension, and bradycardia have been observed during paclitaxel administration, patients are usually asymptomatic and generally do not require treatment. Frequent vital sign monitoring, particularly during the first hour of paclitaxel infusion, is recommended. Severe cardiovascular events were observed more frequently in patients with NSCLC than breast or ovarian carcinoma. A single case of heart failure related to paclitaxel was seen in the AIDS-KS clinical study.</p><p>&nbsp;</p><p>When Paclitaxel 6 mg/ml is used in combination with doxorubucin or trastuzumab for initial treatment of metastatic breast cancer, attention should be placed on the monitoring of cardiac function. When patients are candidates for treatment with Paclitaxel 6 mg/ml in these combinations, they should undergo baseline cardiac assessment including history, physical examination, ECG, echocardiogram, and/or MUGA scan. Cardiac function should be further monitored during treatment (e.g. every three months). Monitoring may help to identify patients who develop cardiac dysfunction and treating physicians should carefully assess the cumulative dose (mg/m2) of anthracycline administered when making decisions regarding frequency of ventricular function assessment. When testing indicates deterioration in cardiac function, even asymptomatic, treating physicians should carefully assess the clinical benefits of further therapy against the potential for producing cardiac damage, including potentially irreversible damage. If further treatment is administered, monitoring of cardiac function</p><p>&nbsp;</p><p>should be more frequent (e.g. every 1-2 cycles). For more details see Summary of Product Characteristics of trastuzumab or doxorubicin.</p><p>&nbsp;</p><p>Although the occurrence of <em>peripheral neuropathy </em>is frequent, the development of severe symptoms is rare. In severe cases, a dose reduction of 20% (25% for KS patients) for all subsequent courses of paclitaxel is recommended. In NSCLC patients and in ovarian cancer patients treated in the first-line setting, the administration of paclitaxel as a three hour infusion in combination with cisplatin, resulted in a greater incidence of severe neurotoxicity than both single agent paclitaxel and cyclophosphamide followed by cisplatin.</p><p>&nbsp;</p><p>Special care should be taken to avoid <em>intra-arterial </em>application of paclitaxel, since in animal studies testing for local tolerance severe tissue reactions were observed after intra-arterial application.</p><p>&nbsp;</p><p>Paclitaxel in combination with radiation of the lung, irrespective of their chronological order, may contribute to the development of <em>interstitial pneumonitis</em>.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Pseudomembranous colitis </em>has been rarely reported including cases in patients who have not been concomitantly treated with antibiotics. This reaction should be considered in the differential diagnosis of cases of severe or persistent diarrhoea occurring during or shortly after treatment with paclitaxel.</p><p>&nbsp;</p><p>In KS patients, <em>severe mucositis </em>is rare. If severe reactions occur, the paclitaxel dose should be reduced by 25%.</p><p>&nbsp;</p><p>This medicinal product contains macrogolglycerol ricinoleate, which may cause severe allergic reactions.</p><p>&nbsp;</p><p>Since Paclitaxel 6 mg/ml concentrate for solution for infusion contains ethanol (401.7 mg/ml), consideration should be given to possible CNS and other effects.</p><p>&nbsp;</p><p>Paclitaxel has shown to be teratogenic, embryotoxic and mutagenic in many experimental systems. Therefore, sexually active fertile female and male patients should use effective methods of contraception during treatment and up to six months after treatment for men and women (see section 4.6). Hormonal contraception is contraindicated in hormone receptor positive tumors.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The recommended regimen of paclitaxel administration for the first-line chemotherapy of ovarian carcinoma is for paclitaxel to be given <u>before </u>cisplatin. When paclitaxel is given <u>before </u>cisplatin, the safety profile of paclitaxel is consistent with that reported for single-agent use. When paclitaxel was given <u>after </u>cisplatin, patients showed a more profound myelosuppression and an approximately 20% decrease in paclitaxel clearance. Patients treated with paclitaxel and cisplatin may have an increased risk of renal failure as compared to cisplatin alone in gynecological cancers.</p><p>&nbsp;</p><p>Since the elimination of doxorubicin and its active metabolites can be reduced when paclitaxel and doxorubicin are given closer in time, paclitaxel for initial treatment of metastatic breast cancer should be administered 24 hours after doxorubicin (see 5.2).</p><p>&nbsp;</p><p>The metabolism of paclitaxel is catalysed, in part, by cytochrome P450 isoenzymes CYP2C8 and CYP3A4. Therefore, in the absence of a PK drug-drug interaction study, caution should be exercised when administering paclitaxel concomitantly with medicines known to inhibit either CYP2C8 or CYP3A4 (e.g. ketoconazole and other imidazole antifungals, erythromycin, fluoxetine, gemfibrozil, clopidogrel, cimetidine, ritonavir, saquinavir, indinavir, and nelfinavir) because toxicity of paclitaxel may be increased due to higher paclitaxel exposure. Administering paclitaxel concomitantly with medicines known to induce either CYP2C8 or CYP3A4 (e.g. rifampicin, carbamazepine, phenytoin, efavirenz, nevirapine) is not recommended because efficacy may be compromised because of lower paclitaxel exposures.</p><p>Paclitaxel clearance is not affected by cimetidine premedication.</p><p>&nbsp;</p><p>&nbsp;</p><p>Studies in KS patients, who were taking multiple concomitant medicinal products, suggest that the systemic clearance of paclitaxel was significantly lower in the presence of nelfinavir and ritonavir, but not with indinavir. Insufficient information is available on interactions with other protease inhibitors. Consequently, paclitaxel should be administered with caution in patients receiving protease inhibitors as concomitant therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pregnancy</em></p><p>There is no adequate data from the use of paclitaxel in pregnant women. Paclitaxel has been shown to be both embryotoxic and foetotoxic in rabbits, and to reduce fertility in rats. As with other cytotoxic medicinal products, paclitaxel may cause foetal harm when administered to pregnant women.</p><p>Therefore, paclitaxel should not be used during pregnancy unless clearly necessary. Women of childbearing potential receiving paclitaxel should be advised to avoid becoming pregnant, and to inform the treating physician immediately should this occur.</p><p>&nbsp;</p><p><em>Breastfeeding</em></p><p>Paclitaxel is contraindicated during lactation (see section 4.3). It is not known whether paclitaxel is excreted in human milk. Breastfeeding should be discontinued for the duration of therapy.</p><p>&nbsp;</p><p><em>Fertility</em></p><p>Female and male patients of fertile age, and/or their partners should use contraceptions for at least 6 months after treatment with paclitaxel.</p><p>Male patients should seek advice regarding cryoconservation of sperm prior to treatment with paclitaxel because of the possibility of infertility.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Paclitaxel 6 mg/ml has not been demonstrated to interfere with the ability to drive and use machines. However, it should be noted that Paclitaxel 6 mg/ml does contain alcohol (see sections 4.4 and 6.1) and accordingly the ability to drive or to use machines may be decreased</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Unless otherwise noted, the following discussion refers to the overall safety database of 812 patients with solid tumours treated with single-agent paclitaxel in clinical studies. As the KS population is very specific, a special chapter based on a clinical study with 107 patients, is presented at the end of this section.</p><p>&nbsp;</p><p>The frequency and severity of adverse reactions, unless otherwise mentioned, are generally similar between patients receiving paclitaxel for the treatment of ovarian carcinoma, breast carcinoma, or NSCLC. None of the observed toxicities were clearly influenced by age.</p><p>&nbsp;</p><p><em>A significant hypersensitivity reaction </em>with possible fatal outcome (defined as hypotension requiring therapy, angioedema, respiratory distress requiring bronchodilator therapy, or generalised urticaria) occurred in two (&lt; 1%) patients. Thirty-four percent of patients (17% of all courses) experienced minor hypersensitivity reactions. These minor reactions, mainly flushing and rash, did not require therapeutic intervention nor did they prevent continuation of paclitaxel therapy.</p><p>&nbsp;</p><p>The most frequent significant adverse event was <em>bone marrow suppression</em>. Severe neutropenia</p><p>(&lt; 500 cells/mm&sup3;) occurred in 28% of patients, but was not associated with febrile episodes. Only 1% of patients experienced severe neutropenia for &ge; 7 days. Thrombocytopenia was reported in 11% of</p><p>&nbsp;</p><p>patients. Three percent of patients had a platelet count nadir &lt; 50,000/mm&sup3; at least once while on study. Anaemia was observed in 64% of patients, but was severe (Hb &lt; 5 mmol/l) in only 6% of patients. Incidence and severity of anaemia is related to baseline haemoglobin status.</p><p>&nbsp;</p><p><em>Neurotoxicity, </em>mainly <em>peripheral neuropathy</em>, appeared to be more frequent and severe with&nbsp;&nbsp; a 175 mg/m2 3-hour infusion (85% neurotoxicity, 15% severe) than with a 135 mg/m2 24-hour</p><p>infusion (25% peripheral neuropathy, 3% severe) when paclitaxel was combined with cisplatin. In NSCLC patients and in ovarian cancer patients treated with paclitaxel over 3 hours followed by cisplatin, there is an apparent increase in the incidence of severe neurotoxicity. Peripheral neuropathy can occur following the first course and can worsen with increasing exposure to paclitaxel. Peripheral neuropathy was the cause of paclitaxel discontinuation in a few cases. Sensory symptoms have usually improved or resolved within several months of paclitaxel discontinuation. Pre-existing neuropathies resulting from prior therapies are not a contraindication for paclitaxel therapy.</p><p>&nbsp;</p><p><em>Arthralgia or myalgia </em>affected 60% of patients and was severe in 13% of patients.</p><p>&nbsp;</p><p><em>Injection site reactions </em>during intravenous administration may lead to localised oedema, pain, erythema, and induration; on occasion, extravasation can result in cellulitis. Skin sloughing and/or peeling has been reported, sometimes related to extravasation. Skin discoloration may also occur. Recurrence of skin reactions at a site of previous extravasation following administration of paclitaxel at a different site, i.e. &ldquo;recall&rdquo;, has been reported rarely. A specific treatment for extravasation reactions is unknown at this time.</p><p>In some cases, the onset of the injection site reaction either occurred during a prolonged infusion or was delayed by a week to 10 days.</p><p>&nbsp;</p><p>&nbsp;</p><p>The table below lists adverse reactions associated with the administration of single agent paclitaxel administered as a three hour infusion in the metastatic setting (812 patients treated in clinical studies) and as reported in the postmarketing surveillance* of paclitaxel. The latter ones may be attributed to paclitaxel regardless of the treatment regimen.</p><p>&nbsp;</p><p>&nbsp;</p><p>The frequency of adverse reactions listed below is defined using the following convention: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000to &lt; 1/100); rare (&ge; 1/10,000 to</p><p>&lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>Infections and infestations:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Very common</em>: infection (mainly urinary tract and</p><p>upper respiratory tract infections), with reported cases of fatal outcome</p><p><em>Uncommon: </em>septic shock</p><p><em>Rare*: </em>sepsis, peritonitis, pneumonia</p><p><em>Very rare</em> : Pseudomembranous colitis</p><p>&nbsp;</p><p>Blood and lymphatic system disorders:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Very common</em>: myelosuppression, neutropenia,</p><p>anaemia, thrombocytopenia, leucopenia, bleeding</p><p><em>Rare*</em>: febrile neutropenia</p><p><em>Very rare</em>*:acute myeloid leukaemia, myelodysplastic syndrome</p><p><em>Not known: </em>disseminated intravascular coagulation (DIC), often in association with sepsis or multi- organ failure, has been reported.</p><p>&nbsp;</p><p>&nbsp;</p><p>Immune system disorders:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Very common</em>: minor hypersensitivity reactions (mainly flushing and rash)</p><p><em>Uncommon</em>: significant hypersensitivity reactions requiring therapy (e.g., hypotension, angioneurotic oedema, respiratory distress, generalised urticaria, chills, back pain, chest pain, tachycardia, abdominal pain, pain in extremities, diaphoresis and hypertension)</p><p><em>Rare*: </em>anaphylactic reactions</p><p><em>Very rare*: </em>anaphylactic shock</p><p><em>Not Known </em>: Bronchospasm</p><p>&nbsp;</p><p>Metabolism and nutrition disorders:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Very rare*: </em>anorexia</p><p><em>Not known*: </em>Tumor lysis syndrome</p><p><em>Rare*</em>: Dehydration</p><p>&nbsp;</p><p>Psychiatric disorders:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Very rare*</em>: confusional state</p><p>&nbsp;</p><p>Nervous system disorders:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Very common</em>: neurotoxicity (mainly: peripheral</p><p>neuropathy***)</p><p><em>Rare</em>*<em>: </em>motor neuropathy (with resultant minor distal weakness)</p><p><em>Very rare*: </em>grand mal seizures, autonomic neuropathy (resulting in paralytic ileus and orthostatic hypotension), encephalopathy, convulsions, dizziness, ataxia, headache</p><p>&nbsp;</p><p>Eye disorders:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Very rare*: </em>optic nerve and/or visual disturbances (scintillating scotomata), particularly in patients who have received higher doses than recommended</p><p><em>Not known*&nbsp;&nbsp;&nbsp;&nbsp; </em>Macular oedema, photopsia, vitreous floaters</p><p>&nbsp;</p><p>Ear and labyrinth disorders:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Very rare*</em>: hearing loss, ototoxicity, tinnitus,</p><p>vertigo</p><p>&nbsp;</p><p>Cardiac disorders:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Common: </em>bradycardia</p><p><em>Uncommon</em>: myocardial infarction, AV block and syncope, cardiomyopathy, asymptomatic ventricular tachycardia, tachycardia with bigeminy</p><p><em>Rare: </em>Cardiac failure<em>Very rare*</em>: atrial fibrillation, supraventricular tachycardia</p><p>&nbsp;</p><p>&nbsp;</p><p>Vascular disorders:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Very common</em>: hypotension <em>Uncommon: </em>thrombosis, hypertension, thrombophlebitis</p><p><em>Very rare*</em>: shock</p><p><em>Not known: </em>Phlebitis*</p><p>&nbsp;</p><p>Respiratory, thoracic and mediastinal disorders:</p><p>&nbsp;</p><p><em>Rare*: </em>respiratory failure, pulmonary embolism, lung fibrosis, interstitial pneumonia, dyspnoea, pleural effusion</p><p><em>Very rare*:</em>cough</p><p>&nbsp;</p><p>&nbsp;</p><p>Gastrointestinal disorders:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Very common</em>: diarrhoea, vomiting, nausea, mucosal</p><p>&nbsp;</p><p>inflammation</p><p><em>Rare*: </em>bowel obstruction, bowel perforation, ischaemic colitis, pancreatitis</p><p><em>Very rare*: </em>mesenteric thrombosis, pseudomembranous colitis, neutropenic colitis, ascites, oesophagitis, constipation</p><p>&nbsp;</p><p>Hepatobiliary disorders:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Very rare*: </em>hepatic necrosis, hepatic encephalopathy (both with reported cases of fatal outcome)</p><p>&nbsp;</p><p>Skin and subcutaneous tissue disorders:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Very common</em>: alopecia**</p><p><em>Common: </em>transient and mild nail and skin changes</p><p><em>Rare*: </em>pruritus, rash, erythema</p><p><em>Very rare*: </em>Stevens-Johnson syndrome, epidermal necrolysis, erythema multiforme, exfoliative dermatitis, urticaria, onycholysis (patients on therapy should wear sun protection on hands and feet)</p><p><em>Not known*: </em>Scleroderma, palmar-plantar erythrodysesthesia syndrome</p><p>&nbsp;</p><p>&nbsp;</p><p>Musculoskeletal and connective tissue disorders:</p><p>&nbsp;</p><p><em>Very common: </em>arthralgia, myalgia</p><p><em>Not known*: </em>Systemic lupus erythematosus,Scleroderma</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>General disorders and administration site conditions:</p><p>&nbsp;</p><p><em>Very common:</em> Mucosal inflammation</p><p><em>Common</em>: injection site reactions (including localised oedema, pain, erythema, induration, on occasion extravasation can result in cellulitis, skin fibrosis and skin necrosis)</p><p><em>Rare*: </em>pyrexia, dehydration, asthenia, oedema, malaise</p><p>&nbsp;</p><p>&nbsp;</p><p>Investigations:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Common</em>: severe elevation in AST (SGOT), severe elevation in alkaline phosphatase</p><p><em>Uncommon: </em>severe elevation in bilirubin</p><p><em>Rare*</em>: increase in blood creatinine</p><p>&nbsp;</p><p>**Alopecia: Alopecia was observed in 87% of patients and was abrupt in onset. Pronounced hair loss of &ge;50% is expected for the majority of patients who experience alopecia.</p><p><!--[if gte vml 1]><v:line
 id="_x0000_s1026" style='position:absolute;left:0;text-align:left;z-index:-251658752;
 mso-position-horizontal-relative:page' from="87.35pt,12.2pt" to="90.5pt,12.2pt"
 strokeweight="1.32pt">
 <w:wrap anchorx="page"/>
</v:line><![endif]--><img width="7" height="3" src="file:///C:/Users/abulase1/AppData/Local/Temp/2/msohtmlclip1/01/clip_image001.gif" />*** can persist beyond 6 months of paclitaxel discontinuation</p><p>&nbsp;</p><p>Breast cancer patients who received paclitaxel in the adjuvant setting following AC experienced more neurosensory toxicity, hypersensitivity reactions, arthralgia/myalgia, anaemia, infection, fever, nausea/vomiting and diarrhoea than patients who received AC alone. However, the frequency of these events was consistent with the use of single agent paclitaxel, as reported above.</p><p>&nbsp;</p><p><u>Combination treatment</u></p><p>The following discussion refers to two major trials for the first-line chemotherapy of ovarian carcinoma (paclitaxel + cisplatin: over 1050 patients); two phase III trials in the first line treatment of metastatic breast cancer: one investigating the combination with doxorubicin (paclitaxel + doxorubicin: 267 patients), another one investigating the combination with trastuzumab (planned subgroup analysis paclitaxel + trastuzumab: 188 patients) and two phase III trials for the treatment of advanced NSCLC (paclitaxel + cisplatin: over 360 patients) (see section 5.1).</p><p>&nbsp;</p><p>&nbsp;</p><p>When administered as a three hour infusion for the first-line chemotherapy of ovarian cancer, neurotoxicity, arthralgia/myalgia, and hypersensitivity were reported as more frequent and severe by patients treated with paclitaxel followed by cisplatin than patients treated with cyclophosphamide followed by cisplatin. Myelosuppression appeared to be less frequent and severe with paclitaxel as a three hour infusion followed by cisplatin compared with cyclophosphamide followed by cisplatin.</p><p>&nbsp;</p><p>For the first line chemotherapy of metastatic breast cancer, neutropenia, anaemia, peripheral neuropathy, arthralgia/myalgia, asthenia, fever, and diarrhoea were reported more frequently and with greater severity when paclitaxel (220 mg/m&sup2;) was administered as a 3-hour infusion 24 hours following doxorubicin (50 mg/m&sup2;) when compared to standard FAC therapy (5-FU 500 mg/m&sup2;, doxorubicin 50 mg/m&sup2;, cyclophosphamide 500 mg/m&sup2;). Nausea and vomiting appeared to be less frequent and severe with the paclitaxel (220 mg/m&sup2;) / doxorubicin (50 mg/m&sup2;) regimen as compared to the standard FAC regimen. The use of corticosteroids may have contributed to the lower frequency and severity of nausea and vomiting in the paclitaxel/doxorubicin arm.</p><p>&nbsp;</p><p>When paclitaxel was administered as a 3-hour infusion in combination with trastuzumab for the first line treatment of patients with metastatic breast cancer, the following events (regardless of relationship to paclitaxel or trastuzumab) were reported more frequently than with single agent paclitaxel: heart failure (8% vs. 1%), infection (46% vs. 27%), chills (42% vs. 4%), fever (47% vs. 23%), cough (42%</p><p>vs. 22%), rash (39% vs. 18%), arthralgia (37% vs. 21%), tachycardia (12% vs. 4%), diarrhoea (45%</p><p>vs. 30%), hypertonia (11% vs. 3%), epistaxis (18% vs. 4%), acne (11% vs. 3%), herpes simplex (12%</p><p>vs. 3%), accidental injury (13% vs. 3%), insomnia (25% vs. 13%), rhinitis (22% vs. 5%), sinusitis (21% vs. 7%), and injection site reaction (7% vs. 1%). Some of these frequency differences may be due to the increased number and duration of treatments with paclitaxel/trastuzumab combination vs. single agent paclitaxel. Severe events were reported at similar rates for paclitaxel/trastuzumab and single agent paclitaxel.</p><p>&nbsp;</p><p>Further, it has been demonstrated that peripheral neuropathies can persist beyond 6 months of paclitaxel discontinuation.</p><p>&nbsp;</p><p>When doxorubicin was administered in combination with paclitaxel in metastatic breast cancer, <em>cardiac contraction abnormalities </em>(&ge; 20% reduction of left ventricular ejection fraction) were observed in 15% of patients vs. 10% with standard FAC regimen. <em>Congestive heart failure </em>was observed in &lt; 1% in both paclitaxel/doxorubicin and standard FAC arms. Administration of trastuzumab in combination with paclitaxel in patients previously treated with anthracyclines resulted in an increased frequency and severity of <em>cardiac dysfunction </em>in comparison with patients treated with paclitaxel single agent (NYHA Class I/II 10% vs. 0%; NYHA Class III/IV 2% vs. 1%) and rarely has been associated with death (see trastuzumab Summary of Product Characteristics). In all but these rare cases, patients responded to appropriate medical treatment.</p><p><em>Radiation pneumonitis </em>has been reported in patients receiving concurrent radiotherapy. <u>AIDS-related Kaposi&rsquo;s sarcoma</u></p><p>Except for haematologic and hepatic undesirable effects (see below), the frequency and severity of undesirable effects are generally similar between KS patients and patients treated with paclitaxel monotherapy for other solid tumours, based on a clinical study including 107 patients.</p><p>&nbsp;</p><p><em>Blood and the lymphatic system disorders: </em>bone marrow suppression was the major dose-limiting toxicity. Neutropenia is the most important haematological toxicity. During the first course of treatment, severe neutropenia (&lt; 500 cells/mm3) occurred in 20% of patients. During the entire treatment period, severe neutropenia was observed in 39% of patients. Neutropenia was present for</p><p>&nbsp;</p><p>&gt; 7 days in 41% and for 30-35 days in 8% of patients. It resolved within 35 days in all patients who were followed. The incidence of Grade 4 neutropenia lasting &ge; 7 days was 22%.</p><p>&nbsp;</p><p>Neutropenic fever related to paclitaxel was reported in 14% of patients and in 1.3% of treatment cycles. There were 3 septic episodes (2.8%) during paclitaxel administration related to the medicinal product that proved fatal.</p><p>&nbsp;</p><p>Thrombocytopenia was observed in 50% of patients, and was severe (&lt; 50,000 cells/mm3) in 9%. Only 14% experienced a drop in their platelet count &lt; 75,000 cells/mm3, at least once while on treatment.</p><p>Bleeding episodes related to paclitaxel were reported in &lt; 3% of patients, but the haemorrhagic episodes were localised.</p><p>&nbsp;</p><p>Anaemia (Hb &lt; 11 g/dl) was observed in 61% of patients and was severe (Hb &lt; 8 g/dl) in 10%. Red cell transfusions were required in 21% of patients.</p><p>&nbsp;</p><p><em>Hepatobiliary disorders: </em>among patients (&gt; 50% on protease inhibitors) with normal baseline liver function, 28%, 43% and 44% had elevations in bilirubin, alkaline phosphatase and AST (SGOT), respectively. For each of these parameters, the increases were severe in 1% of cases.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no known antidote for paclitaxel overdose. In case of overdose, the patient should be closely monitored. Treatment should be directed at the primary anticipated toxicities, which consist of bone marrow suppression, peripheral neurotoxicity and mucositis.</p><p>Overdoses in paediatric patients may be associated with acute ethanol toxicity.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antineoplastic agents (taxanes), ATC code: L01C D01.</p><p>&nbsp;</p><p>Paclitaxel is a antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability results in the inhibition of the normal dynamic reorganisation of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or bundles of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.</p><p>&nbsp;</p><p><u>Ovarian carcinoma</u></p><p>In the first-line chemotherapy of ovarian carcinoma, the safety and efficacy of paclitaxel were evaluated in two major, randomised, controlled (vs. cyclophosphamide 750 mg/m2 / cisplatin</p><p>75 mg/m2) trials. In the Intergroup trial (BMS CA139-209), over 650 patients with stage IIb-c, III or IV primary ovarian cancer received a maximum of 9 treatment courses of paclitaxel (175 mg/m2 over</p><p>3 hours) followed by cisplatin (75 mg/m2) or control. The second major trial (GOG-111/BMS</p><p>CA139-022) evaluated a maximum of 6 courses of either paclitaxel (135 mg/m&sup2; over 24 hours) followed by cisplatin (75 mg/m&sup2;) or control in over 400 patients with stage III/IV primary ovarian</p><p>&nbsp;</p><p>cancer, with a &gt; 1 cm residual disease after staging laparotomy, or with distant metastases. While the two different paclitaxel posologies were not compared with each other directly, in both trials patients treated with paclitaxel in combination with cisplatin had a significantly higher response rate, longer time to progression, and longer survival time when compared with standard therapy. Increased neurotoxicity, arthralgia/myalgia but reduced myelosuppression were observed in advanced ovarian cancer patients administered 3-hour infusion paclitaxel/cisplatin as compared to patients who received cyclophosphamide/cisplatin.</p><p>&nbsp;</p><p><u>Breast carcinoma</u></p><p>In the adjuvant treatment of breast carcinoma, 3121 patients with node positive breast carcinoma were treated with adjuvant paclitaxel therapy or no chemotherapy following four courses of doxorubicin and cyclophosphamide (CALGB 9344, BMS CA 139-223). Median follow-up was 69 months.</p><p>Overall, paclitaxel patients had a significant reduction of 18% in the risk of disease recurrence relative to patients receiving AC alone (p = 0.0014), and a significant reduction of 19% in the risk of death&nbsp;&nbsp;&nbsp; (p = 0.0044) relative to patients receiving AC alone. Retrospective analyses show benefit in all patient subsets. In patients with hormone receptor negative/ unknown tumours, reduction in risk of disease recurrence was 28% (95% CI: 0.59-0.86). In the patient subgroup with hormone receptor positive tumours, the risk reduction of disease recurrence was 9% (95% CI: 0.78-1.07). However, the design of the study did not investigate the effect of extended AC therapy beyond 4 cycles. It cannot be excluded on the basis of this study alone that the observed effects could be partly due to the difference in duration of chemotherapy between the two arms (AC 4 cycles; AC + paclitaxel 8 cycles). Therefore, adjuvant treatment with paclitaxel should be regarded as an alternative to extended AC therapy.</p><p>In a second large clinical study in adjuvant node positive breast cancer with a similar design, 3060 patients were randomized to receive or not four courses of paclitaxel at a higher dose of</p><p>225 mg/m&sup2; following four courses of AC (NSABP B-28, BMS CA139-270). At a median follow-up of 64 months, paclitaxel patients had a significant reduction of 17% in the risk of disease recurrence relative to patients who received AC alone (p = 0.006); paclitaxel treatment was associated with a reduction in the risk of death of 7% (95%CI: 0.78-1.12). All subset analyses favored the paclitaxel arm. In this study patients with hormone receptor positive tumour had a reduction in the risk of disease recurrence of 23% (95% CI: 0.6-0.92); in the patient subgroup with hormone receptor negative tumour the risk reduction of disease recurrence was 10% (95%CI: 0.7-1.11).</p><p>&nbsp;</p><p>In the first-line treatment of metastatic breast cancer, the efficacy and safety of paclitaxel were evaluated in two pivotal, phase III, randomised, and controlled open-label trials.</p><p>□&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the first study (BMS CA139-278), the combination of bolus doxorubicin (50 mg/m&sup2;) followed after 24 hours by paclitaxel (220 mg/m&sup2; by 3-hour infusion) (AT), was compared versus standard FAC regimen (5-FU 500 mg/m&sup2;, doxorubicin 50 mg/m&sup2;, cyclophosphamide&nbsp; 500 mg/m&sup2;), both administered every three weeks for eight courses. In this randomised study, 267 patients with metastatic breast cancer, who had either received no prior chemotherapy or only non-anthracycline chemotherapy in the adjuvant setting, were enrolled. Results showed a significant difference in time to progression for patients receiving AT compared to those receiving FAC (8.2 vs. 6.2 months; p = 0.029). The median survival was in favour of paclitaxel/doxorubicin vs. FAC (23.0 vs. 18.3 months; p = 0.004). In the AT and FAC treatment arm 44% and 48% respectively received follow-up chemotherapy which included taxanes in 7% and 50% respectively. The overall response rate was also significantly higher in the AT arm compared to the FAC arm (68% vs. 55%). Complete responses were seen in 19% of the paclitaxel/doxorubicin arm patients vs. 8% of the FAC arm patients. All efficacy results have been subsequently confirmed by a blinded independent review.</p><p>□&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the second pivotal study, the efficacy and safety of the paclitaxel and trastuzumab combination was evaluated in a planned subgroup analysis (metastatic breast cancer patients who formerly received adjuvant anthracyclines) of the study HO648g. The efficacy of trastuzumab in combination with paclitaxel in patients who did not receive prior adjuvant anthracyclines has not been proven. The combination of trastuzumab (4 mg/kg loading dose</p><p>&nbsp;</p><p>then 2 mg/kg weekly) and paclitaxel (175 mg/m&sup2;) 3-hour infusion, every three weeks was compared to single-agent paclitaxel (175 mg/m&sup2;) 3-hour infusion, every three weeks in 188 patients with metastatic breast cancer overexpressing HER2 (2+ or 3+ as measured by</p><p>immunohistochemistry), who had previously been treated with anthracyclines. paclitaxel was administered every three weeks for at least six courses while trastuzumab was given weekly until disease progression. The study showed a significant benefit for the paclitaxel/trastuzumab combination in terms of time to progression (6.9 vs. 3.0 months), response rate (41% vs. 17%), and duration of response (10.5 vs. 4.5 months) when compared to paclitaxel alone. The most significant toxicity observed with the paclitaxel/trastuzumab combination was cardiac dysfunction (see section 4.8).</p><p>&nbsp;</p><p><u>Advanced non-small cell lung carcinoma</u></p><p>In the treatment of advanced NSCLC, paclitaxel 175 mg/m&sup2; followed by cisplatin 80 mg/m&sup2; has been evaluated in two phase III trials (367 patients on paclitaxel containing regimens). Both were randomised trials, one compared to treatment with cisplatin 100 mg/m&sup2;, the other used teniposide 100 mg/m&sup2; followed by cisplatin 80 mg/m&sup2; as comparator (367 patients on comparator). Results in each trial were similar. For the primary outcome of mortality, there was no significant difference between the paclitaxel containing regimen and the comparator (median survival times 8.1 and</p><p>9.5 months on paclitaxel containing regimens, 8.6 and 9.9 months on comparators). Similarly, for progression-free survival there was no significant difference between treatments. There was a significant benefit in terms of clinical response rate. Quality of life results are suggestive of a benefit on paclitaxel containing regimens in terms of appetite loss and provide clear evidence of the inferiority of paclitaxel containing regimens in terms of peripheral neuropathy (p &lt; 0.008).</p><p>&nbsp;</p><p><u>AIDS-related Kaposi&rsquo;s sarcoma</u></p><p>In the treatment of AIDS-related KS, the efficacy and safety of paclitaxel were investigated in a non- comparative study in patients with advanced KS, previously treated with systemic chemotherapy. The primary end-point was best tumour response. Of the 107 patients, 63 were considered resistant to liposomal anthracyclines. This subgroup is considered to constitute the core efficacy population. The overall success rate (complete/partial response) after 15 cycles of treatment was 57% (CI 44-70%) in liposomal anthracycline-resistant patients. Over 50% of the responses were apparent after the first</p><p>3 cycles. In liposomal anthracycline-resistant patients, the response rates were comparable for patients who had never received a protease inhibitor (55.6%) and those who received one at least 2 months prior to treatment with paclitaxel (60.9%). The median time to progression in the core population was 468 days (95% CI 257-NE). Median survival could not be computed, but the lower 95% bound was 617 days in core patients.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following intravenous administration, paclitaxel exhibits a biphasic decline in plasma concentrations.</p><p>&nbsp;</p><p>The pharmacokinetics of paclitaxel were determined following 3 and 24 hour infusions at doses of 135 and 175 mg/m&sup2;. Mean terminal half-life estimates ranged from 3.0 to 52.7 hours, and mean, non- compartmentally derived, values for total body clearance ranged from 11.6 to 24.0 l/h/m&sup2;; total body clearance appeared to decrease with higher plasma concentrations of paclitaxel. Mean steady-state volume of distribution ranged from 198 to 688 l/m&sup2;, indicating extensive extravascular distribution and/or tissue binding. With the 3-hour infusion, increasing doses result in non-linear pharmacokinetics. For the 30% increase in dose from 135 mg/m&sup2; to 175 mg/m&sup2;, the Cmax and AUC0&reg;&yen;&nbsp;values increased 75% and 81%, respectively.</p><p>&nbsp;</p><p>Following an intravenous dose of 100 mg/m&sup2; given as a 3-hour infusion to 19 KS patients, the mean Cmax was 1,530 ng/ml (range 761-2,860 ng/ml) and the mean AUC 5,619 ng&middot;h/ml (range</p><p>&nbsp;</p><p>2,609-9,428 ng&middot;h/ml). Clearance was 20.6 l/h/m&sup2; (range 11-38) and the volume of distribution was 291 l/m&sup2; (range 121-638). The terminal elimination half-life averaged 23.7 hours (range 12-33).</p><p>&nbsp;</p><p>Intrapatient variability in systemic paclitaxel exposure was minimal. There was no evidence for accumulation of paclitaxel with multiple treatment courses.</p><p>&nbsp;</p><p><em>In vitro </em>studies of binding to human serum proteins indicate that 89-98% of medicinal product is bound. The presence of cimetidine, ranitidine, dexamethasone or diphenhydramine did not affect protein binding of paclitaxel.</p><p>&nbsp;</p><p>The disposition of paclitaxel has not been fully elucidated in humans. Mean values for cumulative urinary recovery of unchanged drug have ranged from 1.3 to 12.6% of the dose, indicating extensive non-renal clearance. Hepatic metabolism and biliary clearance may be the principal mechanism for disposition of paclitaxel. Paclitaxel appears to be metabolised primarily by cytochrome P450 enzymes. Following administration of a radiolabelled paclitaxel, an average of 26, 2 and 6% of the radioactivity was excreted in the faeces as 6&alpha;-hydroxypaclitaxel, 3&rsquo;-p-hydroxypaclitaxel, and 6&alpha;-3&rsquo;-p-dihydroxy- paclitaxel, respectively. The formation of these hydroxylated metabolites is catalysed by CYP2C8, - 3A4, and both -2C8 and -3A4 respectively. The effect of renal or hepatic dysfunction on the disposition of paclitaxel following a 3-hour infusion has not been investigated formally.</p><p>Pharmacokinetic parameters obtained from one patient undergoing haemodialysis who received a 3-hour infusion of paclitaxel 135 mg/m&sup2; were within the range of those defined in non-dialysis patients.</p><p>&nbsp;</p><p>In clinical trials where paclitaxel and doxorubicin were administered concomitantly, the distribution and elimination of doxorubicin and its metabolites were prolonged. Total plasma exposure to doxorubicin was 30% higher when paclitaxel immediately followed doxorubicin than when there was a 24-hour interval between medicinal products.</p><p>&nbsp;</p><p>For use of paclitaxel in combination with other therapies, please consult the Summary of Product Characteristics of cisplatin, doxorubicin or trastuzumab for information on the use of these medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The carcinogenic potential of paclitaxel has not been studied. However, paclitaxel is a potential carcinogenic and genotoxic agent, based upon its pharmacodynamic mechanism of action. paclitaxel has been shown to be mutagenic in both <em>in vitro </em>and <em>in vivo </em>mammalian test systems.</p><p>Paclitaxel has also been shown to be both embryotoxic and foetotoxic in rabbits, and to reduce fertility in rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ethanol, anhydrous</p><p>Polyoxyl castor oil (macrogolglycerol ricinoleate)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The polyethoxylated castor oil may result in DEHP [di(2-ethylhexyl)phthalate] leaching from plasticised polyvinylchloride (PVC) containers at levels which increase with time and concentration.</p><p>&nbsp;</p><p>Consequently, the preparation, storage and administration of diluted Paclitaxel should be carried out using non-PVC-containing equipment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Vial before opening
 2  years

After opening before dilution
Chemical and physical in-use stability has been demonstrated for 28 days below 25°C following multiple needle entries and product withdrawal.
From a microbiological point of view, once opened the product may be stored for a maximum of 28 days below 25°C. Other in-use storage times and conditions are the responsibility of the user.

After dilution
Chemical and physical stability after dilution is documented for 51 hours below 25 ºC and 2-8 ºC. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep the vial in the outer carton in order to protect from light. This medicinal product does not require any special temperature storage conditions</p><p>&nbsp;</p><p>For diluted solutions, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glass vial (type I) with a fluoropolymer-coated halobutyl rubber stopper and aluminium crimp caps containing paclitaxel 30 mg/5 ml, 100 mg/16.7 ml, 150 mg/25 ml, 300 mg/50 ml or 600 mg/100 ml.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Package sizes:</u></p><p>1 vial, 5 vials, 10 vials and 20 vials containing 30 mg paclitaxel.</p><p>1 vial, 5 vials, 10 vials and 20 vials containing 100 mg paclitaxel.</p><p>1 vial, 5 vials, 10 vials and 20 vials containing 150 mg paclitaxel.</p><p>1 vial, 5 vials, 10 vials and 20 vials containing 300 mg paclitaxel.</p><p>1 vial, 5 vials, 10 vials and 20 vials containing 600 mg paclitaxel.</p><p>&nbsp;</p><p>The 1, 5 or 10 vials are available with or without a protective plastic overwrap (ONCO-SAFE) in a carton.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Handling:</p><p>&nbsp;</p><p>Protection instructions for preparation of Paclitaxel solution for infusion:</p><p>&nbsp;</p><p>Protective chamber should be used and protective gloves as well as protective gown should be worn. If there is no protective chamber available mouth cover and goggles should be used.</p><p>&nbsp;</p><p>As with all antineoplastic agents, caution should be exercised when handling paclitaxel.</p><p>&nbsp;</p><p>Pregnant women or women of childbearing potential must be warned to avoid handling cytotoxic agents.</p><p>&nbsp;</p><p>Opened containers, like injection vials and infusion bottles and used cannulas, syringes, catheters, tubes, and residuals of cytostatics should be considered as hazardous waste and undergo disposal according to local guidelines for the handling of HAZARDOUS WASTE.</p><p>&nbsp;</p><p>As with all antineoplastic agents, caution should be exercised when handling paclitaxel.</p><p>&nbsp;</p><p>Pregnant women or women of childbearing potential must be warned to avoid handling cytotoxic agents.</p><p>&nbsp;</p><p>&nbsp;</p><p>Dilution should be carried out under aseptic conditions by trained personnel in a designated area. Adequate protective gloves should be worn. Contact with skin and mucous membranes should be avoided. In case of contact with skin, the skin should be washed with soap and water. Following topical exposure, tingling, burning and redness have been observed.&nbsp; In case of contact with the mucous membranes, these should be flushed thoroughly with water. Upon inhalation, dyspnoea, chest pain, burning throat and nausea have been reported.</p><p>&nbsp;</p><p>In the event of contact of Paclitaxel Concentrate for Solution for Infusion with the skin, the area should be rinsed with plenty of running water and then washed with soap and water. In case of contact with mucous membranes, wash the contacted area thoroughly with water. If you have any discomfort, contact a doctor.</p><p>In case of contact of Paclitaxel Concentrate for Solution for Infusion with eyes, wash them thoroughly with plenty of cold water. Contact an ophthalmologist immediately</p><p>&nbsp;</p><p>If unopened vials are refrigerated, a precipitate may form that redissolves with little or no agitation upon reaching room temperature. Product quality is not affected. If the solution remains cloudy or if an insoluble precipitate is noted, the vial should be discarded.</p><p>&nbsp;</p><p>Following multiple needle entries and product withdrawals, the vials maintain microbial, chemical and physical stability for up to 28 days at 25&deg;C. Other in-use storage times and conditions are the responsibility of the user.</p><p>&nbsp;</p><p><strong>Preparation for IV administration</strong>: Prior to infusion, paclitaxel must be diluted using aseptic techniques in 0.9% Sodium Chloride Injection, or 5% Dextrose Injection, or 5% Dextrose and 0.9% Sodium Chloride Injection to a final concentration of 0.3 to 1.2 mg/ml.</p><p>&nbsp;</p><p>Chemical and physical in-use stability of the solution prepared for infusion has been demonstrated at 5&deg;C and at 25&deg;C for 51 hours when diluted in 5% Dextrose solution, and for 51 hours when diluted in 0.9% Sodium Chloride Injection. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8&deg;C, unless dilution has taken place in controlled and validated aseptic conditions.</p><p>After dilution the solution is for single use only.</p><p>&nbsp;</p><p>Upon preparation, solutions may show haziness, which is attributed to the formulation vehicle, and is not removed by filtration. Paclitaxel should be administered through an in-line filter with a microporous membrane &pound; 0.22 mm. No significant losses in potency have been noted following simulated delivery of the solution through IV tubing containing an in-line filter.</p><p>&nbsp;</p><p>There have been rare reports of precipitation during paclitaxel infusions, usually towards the end of a 24 hour infusion period. Although the cause of this precipitation has not been elucidated, it is probably linked to the supersaturation of the diluted solution. To reduce the precipitation risk, paclitaxel should be used as soon as possible after dilution, and excessive agitation, vibration or shaking should be avoided. The infusion sets should be flushed thoroughly before use. During infusion, the appearance of the solution should be regularly inspected and the infusion should be stopped if precipitation is present.</p><p>&nbsp;</p><p>To minimise patient exposure to DEHP, which may be leached from plasticised PVC infusion bags, sets, or other medical instruments, diluted Paclitaxel &ldquo;Meda&rdquo; solutions should be stored in bottles without PVC (glass, polypropylene) or plastic bags (polypropylene, polyolefin) and administered through polyethylene-lined administration sets. Use of filter devices which incorporate short inlet and/or outlet plasticised PVC tubing has not resulted in significant leaching of DEHP.</p><p>&nbsp;</p><p>Disposal:</p><p>All items used for preparation, administration or otherwise coming into contact with paclitaxel should undergo disposal according to local guidelines for the handling of cytotoxic compounds.</p><p>&nbsp;</p><p>Follow the instructions below in case of spillage: - protective clothing should be worn - broken glass should be collected and placed in the container for HAZARDOUS WASTE - contaminated surfaces should be flushed properly with copious amounts of cold water - the flushed surfaces should then be wiped thoroughly and the materials used for wiping should be dispos</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EBEWE PHARMA GES.M.B.H NFG. KG,        
 UNTERACH,         
  AUSTRIA

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                06/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>